2026 INTERIM REPORT

LifeTech Scientific Corporation
先健科技公司

(Incorporated in the Cayman Islands with limited liability)

Stock Code: 01302

CONTENTS

CORPORATE INFORMATION

As at 28 August 2026

EXECUTIVE DIRECTORS

XIE Yuehui
(Chairman and Chief Executive Officer)
LIU Jianxiong *(resigned on 22 May 2026)*
WU Liping
FANG Yu
FENG Xiaoling (*resigned on 22 May 2026*)

INDEPENDENT NON-EXECUTIVE DIRECTORS

ZHOU Luming
WANG Wansong *(resigned on 26 January 2026)*
CHEN Dongxia
JIANG Feng *(redesignated on 18 June 2026)*

COMPANY SECRETARY

LIU Jianxiong

AUTHORISED REPRESENTATIVES

XIE Yuehui
LIU Jianxiong (*resigned on 22 May 2026*)
FANG Yu *(appointed on 12 August 2026)*

AUDIT COMMITTEE

CHEN Dongxia *(Chairlady)*
ZHOU Luming
WANG Wansong *(resigned on 26 January 2026)*
JIANG Feng *(appointed on 18 June 2026)*

NOMINATION COMMITTEE

ZHOU Luming *(Chairman)*
XIE Yuehui
WANG Wansong *(resigned on 26 January 2026)*
CHEN Dongxia
FENG Xiaoling *(resigned on 22 May 2026)*

REMUNERATION COMMITTEE

CHEN Dongxia *(Chairlady)*
WANG Wansong *(resigned on 26 January 2026)*
XIE Yuehui
JIANG Feng *(appointed on 18 June 2026)*

HONG KONG SHARE REGISTRAR

Tricor Investor Services Limited
17/F, Far East Finance Centre
16 Harcourt Road, Hong Kong

WEBSITE

www.lifetechmed.com

STOCK CODE

1302

LISTING DATE ON THE GROWTH ENTERPRISE MARKET

10 November 2011

DATE OF TRANSFER OF LISTING FROM THE GROWTH ENTERPRISE MARKET TO THE MAIN BOARD

6 November 2013

PRINCIPAL BANKERS

China Merchants Bank Co., Ltd.
Shenzhen Chegongmiao Branch
Block A, 1/F, Tianxiang Building
Chegongmiao Tianan Industrial District
Futian, Shenzhen, PRC

China Construction Bank Corporation, Qianhai Branch
Block B, Minsheng Internet Building, Qianhai
Shenzhen, PRC

HONG KONG LEGAL ADVISER

Allen Overy Shearman Sterling
9/F, Three Exchange Square
Central
Hong Kong SAR

AUDITOR

Deloitte Touche Tohmatsu
Registered Public Interest Entity Auditors
35/F, One Pacific Place
88 Queensway
Hong Kong

REGISTERED OFFICE IN CAYMAN ISLANDS

PO Box 309
Ugland House
Grand Cayman, KY1-1104
Cayman Islands

PRINCIPAL PLACE OF BUSINESS AND ADDRESS OF HEADQUARTERS

LifeTech Scientific Building
No.22, Keji 12th Road South
High-tech Industrial Park
Nanshan District
Shenzhen 518063, PRC

PLACE OF BUSINESS IN HONG KONG REGISTERED UNDER PART 16 OF THE HONG KONG COMPANIES ORDINANCE

31/F, 148 Electric Road
North Point
Hong Kong

PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE

Maples Fund Services (Cayman) Limited
PO Box 1093, Boundary Hall
Cricket Square, Grand Cayman, KY1-1102
Cayman Islands

FINANCIAL HIGHLIGHTS

The board (the "Board") of directors (the "Directors", each a "Director") of LifeTech Scientific Corporation (the "Company" or "Lifetech") is pleased to announce the unaudited consolidated results of the Company and its subsidiaries (collectively the "Group") for the six months ended 30 June 2026 (the "Reporting Period") together with the comparative figures for the corresponding period of 2025.

	Six months ended 30 June		
	2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)	Change
Revenue	**600,830**	676,707	(11.2%)
Gross profit	**465,896**	497,755	(6.4%)
Operating (loss) profit	**(11,256)**	64,387	(117.5%)
(Loss) profit for the period	**(48,283)**	41,765	(215.6%)
(Loss) profit for the period attributable to owners of the Company	**(34,348)**	55,074	(162.4%)
(Loss) earnings per share			
– Basic (RMB cents)	**(0.8)**	1.3	(161.5%)
– Diluted (RMB cents)	**(0.8)**	1.3	(161.5%)

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)	Change
Assets			
Non-current assets	**2,679,065**	2,687,294	(0.3%)
Current assets	**2,070,310**	2,325,134	(11.0%)
Total assets	**4,749,375**	5,012,428	(5.2%)
Liabilities			
Current liabilities	**844,846**	1,479,408	(42.9%)
Non-current liabilities	**635,977**	57,912	998.2%
Total liabilities	**1,480,823**	1,537,320	(3.7%)
Total equity	**3,268,552**	3,475,108	(5.9%)

BUSINESS OVERVIEW

The Group is a developer, manufacturer and marketer of advanced minimally invasive interventional medical devices for cardiovascular, peripheral vascular diseases and disorders. We have three main product lines, covering the structural heart diseases business, the peripheral vascular diseases business and the cardiac pacing and electrophysiology business. Structural heart diseases related products mainly include the congenital heart diseases occluders and Left Atrial Appendage ("LAA") occluders; peripheral vascular diseases related products mainly include vena cava filters and stent grafts; and cardiac pacing and electrophysiology related products mainly include cardiac pacemakers. These three product lines provide clinically effective and commercially attractive product offerings. The Group has built a strong sales network globally and has distributors in numerous countries across Asia, Europe, North America, South America and Africa.

FIRST-HALF PERFORMANCE

The Group recorded a revenue of approximately RMB600.8 million for the six months ended 30 June 2026, representing a decrease of approximately RMB75.9 million or approximately 11.2% as compared with the revenue of approximately RMB676.7 million for the corresponding period of 2025. China's mainland remained our largest market, where the revenue generated accounted for approximately 69.6% of our total revenue for the six months ended 30 June 2026 (corresponding period of 2025: approximately 74.1%). Meanwhile, Asia (excluding China's mainland) and Europe were our two largest overseas markets, which accounted for approximately 10.3% and 12.6%, respectively, of our total revenue for the six months ended 30 June 2026 (corresponding period of 2025: approximately 11.4% and 11.0%, respectively). For the six months ended 30 June 2026, domestic sales of the Group decreased by approximately 16.6% as compared with the corresponding period of 2025, while overseas sales of the Group increased by approximately 4.1% (approximately 8.2% in USD). The growth in overseas sales was mainly attributable to the Company's active expansion of overseas business and effective marketing strategies.

Net profit attributable to owners of the Company for the six months ended 30 June 2026, excluding certain non-recurring items as set out below, was approximately RMB114.8 million as compared with the net profit amounting to approximately RMB238.5 million for the six months ended 30 June 2025, representing a decrease of approximately 51.9%. The decrease was mainly due to (i) a decrease in revenue, which amounted to approximately RMB75.9 million; and (ii) a decrease in net exchange gains, which amounted to approximately RMB56.8 million (net exchange losses of approximately RMB32.8 million for the six months ended 30 June 2026, as compared with net exchange gains of approximately RMB24.0 million in the corresponding period of 2025).

The above-mentioned non-recurring items include (i) the other losses arising from financial assets at fair value through profit or loss ("FVTPL") of approximately RMB0.8 million for the six months ended 30 June 2026 (corresponding period of 2025: gains of approximately RMB9.9 million); (ii) the share-based payment expenses of approximately RMB123.1 million for the six months ended 30 June 2026 (corresponding period of 2025: approximately RMB193.5 million); and (iii) the transaction expenses in connection with a proposed transaction involving the conditional acquisition of equity interest in Starway Medical Technology, Inc. (北京華醫聖傑科技有限公司) ("Starway") and the issue of convertible bonds, which the Board has resolved not to proceed with, amounting to approximately RMB25.3 million (corresponding period of 2025: nil). Taking into account the effects of such non-recurring items, the net loss attributable to owners of the Company for the six months ended 30 June 2026 was approximately RMB34.3 million, representing a decrease of approximately 162.3% as compared with net profit of approximately RMB55.1 million for the six months ended 30 June 2025.

SALES AND MARKETING

The Group has an experienced team of sales and marketing professionals that are dedicated to support and manage existing distribution networks and to explore new markets. We enhanced the brand awareness and influence of our products by organizing or participating in domestic and international medical conferences, academic activities, seminars, live broadcasts of surgical procedures and delivering trainings to medical professionals. Meanwhile, the Lifetech Knowledge Exchange Program connected cardiovascular experts around the world for academic exchanges. These experts exchanged valuable medical experience and clinical skills which were highly conducive to promoting the development of medical technology in the field of minimally invasive cardiovascular interventions. Such activities showcased our strengths in product innovation and helped enhance the Company's sales and influence in the international medical community.

RESEARCH AND DEVELOPMENT ("R&D")

The Company's independently developed innovative domestic medical device products will maintain the competitive strength of the Company and also provide more effective treatments to patients around the world. In the first half of 2026, the Company continuously strengthened its innovation capabilities and accelerated the development of products, so as to maintain its industry leading position.

During the six months ended 30 June 2026, we have achieved the following milestones in the R&D field:

- Iliac Bifurcation Device (consisting of the G-iliac™ Pro Iliac Bifurcation Stent Graft System and SilverFlow™ Pro Internal Iliac Stent Graft System) and Peripheral High Pressure Balloon Dilatation Catheter have obtained the National Medical Products Administration ("NMPA") certification;

- G-iliac™ Iliac Bifurcation Stent Graft System and SilverFlow™ Internal Iliac Stent Graft System have obtained the CE MDR (Medical Device Regulation) certification;

- Cera™ PFO Occluder, CeraFlex™ PFO Occluder, FuStar™ Steerable Introducer, SeQure™ Snare System and SteerEase™ Introducer have obtained the CE MDR certification. Such products have previously obtained the CE MDD (Medical Device Directive) certification;

- Cera™ PFO Occluder, Yuranos™ Pro Abdominal Aortic Stent Graft System and Constraining Structure PTA Balloon Catheter, etc. are pending registration approval in China;

- Aortic Stent Graft System (consisting of the Ankura™ Pro Aortic Stent Graft System and Longuette™ Aortic Branch Stent Graft System), Fitaya™ Vena Cava Filter System, Futhrough™ Stent Graft Balloon Catheter, Yuranos™ Abdominal Aortic Stent Graft System, Thoracoabdominal Artery Stent Graft System (consisting of the G-Branch™ Thoracoabdominal Aortic Stent Graft System, SilverFlow™ PV Peripheral Vascular Stent Graft System, G-Branch™ AE Main Body Extension Stent Graft System, G-Branch™ AAA Bifurcated Stent Graft System and G-Branch™ IE Iliac Extension Stent Graft System) and Aortic Arch Stent Graft System (consisting of the Ankura™ Plus Aortic Arch Stent Graft System and CSkirt™ Aortic Arch Branch Stent Graft System) are pending registration approval of CE certification;

- X-Clip™ Mitral Valve Clip System and Nitinol Patent Ductus Arteriosus Occluder are currently at the stage of pre-registration clinical enrollment in China;
- CS™ Concave Supra-arch Branched Stent-Graft System and SureCham™ Aortic Arch Single Branch Stent Graft System (consisting of the Aortic Arch Stent Graft System and Aortic Branch Stent Graft System) have completed pre-marketing clinical enrollment and are currently under clinical follow-up in China;
- IBS Titan™ Sirolimus-Eluting Iron Bioresorbable Peripheral Scaffold System is currently at the stage of clinical enrollment in China and in Europe, and its CE registration application has been submitted;
- IBS™ Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System has successfully completed the five-year follow-up of the phase I clinical study and the three-year follow-up of the phase II and III clinical study, further confirming its safety and efficacy. Additionally, its CE and NMPA registration application have been submitted; and
- CS™ Concave Supra-arch Branched Stent-Graft System has been admitted into the NMPA Special Examination and Approval Procedure for Innovative Medical Devices, which is the 17th product of the Company to have obtained admission to the Procedure.

INTELLECTUAL PROPERTY RIGHTS

Intellectual property is an important intangible asset of the Group and also an internal driving force to improve our core competitiveness in the medical device market. During the six months ended 30 June 2026, the Group has filed 50 patent applications and separately, 171 patents were successfully registered. As at 30 June 2026, the Group has filed a total of 2,608 valid patent applications, of which 1,370 patents were registered and valid.

FINANCIAL REVIEW

OVERVIEW

The following discussion is based on, and should be read in conjunction with, the financial information and the notes appended thereto included in this interim report.

REVENUE

The revenue of the Group was approximately RMB600.8 million for the six months ended 30 June 2026, with a decrease of approximately RMB75.9 million or approximately 11.2% as compared with the revenue of approximately RMB676.7 million for the corresponding period of 2025. The decrease was mainly due to the decrease of revenue from sales of structural heart diseases occluders and cardiac pacemakers.

Revenue from the structural heart diseases business

The turnover contributed by the structural heart diseases business for the six months ended 30 June 2026 was approximately RMB200.1 million (corresponding period of 2025: approximately RMB271.5 million), representing a decrease of approximately 26.3% as compared with the corresponding period of 2025.

We have diversified our product portfolio to cover a wide spectrum of the structural heart diseases business, including but not limited to, LAA occluders and three generations of congenital heart diseases occluders namely HeartR, Cera and CeraFlex. As compared with the corresponding period of 2025, the revenue generated from the sales of LAA occluders decreased by approximately 53.8%, and congenital heart diseases occluders decreased by approximately 8.9%.

Revenue from the peripheral vascular diseases business

The turnover contributed by the peripheral vascular diseases business for the six months ended 30 June 2026 was approximately RMB400.7 million (corresponding period of 2025: approximately RMB391.7 million), representing an increase of approximately 2.3% as compared with the corresponding period of 2025.

The products offered in the peripheral vascular diseases business mainly include vena cava filters, Thoracic Aortic Aneurysm stent grafts, Abdominal Aortic Aneurysm stent grafts, Iliac Artery Bifurcation stent grafts, Aortic stent graft systems, Aortic Arch stent graft systems and Thoracoabdominal Aortic stent graft systems. As compared with the corresponding period of 2025, the revenue generated from the sales of stent grafts increased by approximately 2.9%, and the revenue generated from the sales of vena cava filters increased by approximately 2.6%.

Revenue from the cardiac pacing and electrophysiology business

The turnover contributed by the cardiac pacing and electrophysiology business for the six months ended 30 June 2026 was nil (corresponding period of 2025: approximately RMB13.5 million).

GROSS PROFIT AND GROSS PROFIT MARGIN

Gross profit of the Group decreased by approximately 6.4% from approximately RMB497.8 million for the six months ended 30 June 2025 to approximately RMB465.9 million for the six months ended 30 June 2026.

Gross profit margin increased 3.9 percentage points from approximately 73.6% for the six months ended 30 June 2025 to approximately 77.5% for the six months ended 30 June 2026. The increase was mainly due to the change in sales portfolios, resulting from sales contributions from the newly launched products with higher gross profit margins, coupled with the decrease in sales of lower-margin cardiac pacemakers.

OTHER INCOME, EXPENSES, GAINS AND LOSSES

Other income, expenses, gains and losses decreased from gains of approximately RMB50.4 million for the six months ended 30 June 2025 to losses of approximately RMB19.7 million for the six months ended 30 June 2026. The decrease was mainly due to the fluctuation of foreign exchange rates, which resulted in net exchange losses of approximately RMB32.8 million for the six months ended 30 June 2026, as compared with net exchange gains of approximately RMB24.0 million recorded in the corresponding period of 2025.

FINANCIAL ASSETS AT FVTPL

On 25 May 2018, the Group invested USD6.0 million (equivalent to approximately RMB38.2 million) to subscribe for the partnership interest of approximately 9.69% in Ally Bridge Group Innovation Capital Partners III, L.P., a private equity fund established in the Cayman Islands (the "2018 Equity Fund"). The 2018 Equity Fund principally invests in securities or assets of companies in the healthcare industry, with a particular focus on cross-border innovative late-stage venture opportunities and crossover investments. The fair value of our investment in the 2018 Equity Fund as at 30 June 2026 amounted to approximately RMB10.4 million (31 December 2025: approximately RMB8.9 million), representing approximately 0.2% (31 December 2025: approximately 0.2%) of the Company's total assets. Based on the cumulative net distributions of approximately RMB57.8 million by the fund to the Group, coupled with the outlook of the healthcare industry, the Company is optimistic on the prospects of its investments in the 2018 Equity Fund.

On 8 January 2021, the Group invested RMB10.0 million to subscribe for a share of the private securities investment fund. The fair value of this investment as at 30 June 2026 amounted to approximately RMB21.7 million (31 December 2025: approximately RMB16.2 million), representing approximately 0.5% (31 December 2025: approximately 0.3%) of the Company's total assets.

On 24 October 2022, the Group entered into a subscription agreement with certain independent third parties pursuant to which the Group agreed to subscribe in Ally Bridge Group Global Life Science Capital Partners V, L.P. (the "2022 Equity Fund"), as a limited partner, for an aggregate consideration of USD20.0 million (equivalent to approximately RMB144.4 million) in cash. The purposes of the 2022 Equity Fund are to seek capital appreciation primarily by acquiring, holding and disposing of securities, independently or with others, primarily in non-listed or, sometimes, listed entities involved in the healthcare industry, with a particular focus on leading innovative technologies. The fair value of our investment in the 2022 Equity Fund as at 30 June 2026 amounted to approximately RMB191.8 million (31 December 2025: approximately RMB196.0 million), representing approximately 4.0% (31 December 2025: approximately 3.9%) of the Company's total assets.

On 28 November 2023, the Group invested RMB50.0 million to subscribe for a share of the private securities investment fund. The fair value of this investment as at 30 June 2026 amounted to approximately RMB29.0 million (31 December 2025: approximately RMB32.7 million), representing approximately 0.6% (31 December 2025: approximately 0.7%) of the Company's total assets.

On 6 June 2025, the Group entered into a series of agreements through Lifetech Scientific (Shenzhen) Co., Ltd. (先健科技(深圳)有限公司) ("Lifetech Shenzhen"),to make a cash investment in Affector Medtech (Suzhou) Ltd. (劍虎醫療科技(蘇州)有限公司) ("Affector Medtech"), for a total consideration of RMB150.0 million. Upon completion of all stages of the investment, Lifetech Shenzhen will hold 30% equity interest in Affector Medtech. As of 30 June 2026, Lifetech Shenzhen has completed the first stage of capital injection, for a consideration of RMB100.0 million in cash and holds a 22.22% equity interest in Affector Medtech. The fair value change in relation to the financial assets for the six months ended 30 June 2026 is insignificant. The fair value of the Group's investment in Affector Medtech as at 30 June 2026 amounted to RMB100.0 million (31 December 2025: RMB100.0 million), representing approximately 2.1% (31 December 2025: approximately 2.0%) of the Company's total assets.

The aggregate unrealised foreign exchange losses in financial assets at FVTPL were approximately RMB6.4 million for the six months ended 30 June 2026 (corresponding period of 2025: losses of approximately RMB0.9 million), and the aggregate gains from changes in fair value of financial assets at FVTPL were approximately RMB5.5 million (corresponding period of 2025: gains of approximately RMB10.7 million).

The investments are classified as financial assets at FVTPL in accordance with IFRS 9. In the opinion of the Directors, the above investments are held for long-term strategic investment purposes and, as such, the above investments are classified as non-current assets.

SELLING AND DISTRIBUTION EXPENSES

Selling and distribution expenses decreased by approximately 29.0% from approximately RMB250.9 million for the six months ended 30 June 2025 to approximately RMB178.1 million for the six months ended 30 June 2026. The decrease was mainly due to the decrease in staff costs, of which the share-based payment expenses decreased from approximately RMB128.4 million from the six months ended 30 June 2025 to approximately RMB49.6 million for the six months ended 30 June 2026.

ADMINISTRATION EXPENSES

Administration expenses increased by approximately 24.3% from approximately RMB118.4 million for the six months ended 30 June 2025 to approximately RMB147.2 million for the six months ended 30 June 2026. This increase was mainly due to the increase in the transaction expenses in connection with a proposed transaction involving the conditional acquisition of equity interest in Starway and the issue of convertible bonds, which the Board has resolved not to proceed with, amounting to approximately RMB25.3 million (corresponding period of 2025: nil).

R&D EXPENSES

R&D expenses increased by approximately 15.5% from approximately RMB114.5 million for the six months ended 30 June 2025 to approximately RMB132.2 million for the six months ended 30 June 2026. In addition, during the current period, approximately RMB34.9 million (corresponding period of 2025: approximately RMB41.5 million) was capitalised as development expenditure. Taking into account such capitalised expenditure, R&D costs increased by approximately 7.1% from approximately RMB156.0 million for the six months ended 30 June 2025 to approximately RMB167.1 million for the six months ended 30 June 2026. This increase was mainly due to the commencement of amortisation of capitalised development costs for newly registered products, which resulted in an increase in amortisation of intangible assets, as well as an increase in overseas registration fees.

OPERATING PROFIT AND LOSS

During the six months ended 30 June 2026, excluding certain non-recurring items as set out below, the Group recorded an operating profit of approximately RMB137.9 million, as compared with the operating profit of approximately RMB248.0 million for the corresponding period of 2025, representing a decrease of approximately 44.4%. The decrease was mainly due to (i) a decrease in revenue, which amounted to approximately RMB75.9 million; and (ii) a decrease in net exchange gains, which amounted to approximately RMB56.8 million (net exchange losses of approximately RMB32.8 million for the six months ended 30 June 2026, as compared with net exchange gains of approximately RMB24.0 million in the corresponding period of 2025).

The above-mentioned non-recurring items include (i) the other losses arising from financial assets at FVTPL of approximately RMB0.8 million for the six months ended 30 June 2026 (corresponding period of 2025: gains of approximately RMB9.9 million); (ii) the share-based payment expenses of approximately RMB123.1 million for the six months ended 30 June 2026 (corresponding period of 2025: approximately RMB193.5 million); and (iii) the transaction expenses in connection with a proposed transaction involving the conditional acquisition of equity interest in Starway and the issue of convertible bonds, which the Board has resolved not to proceed with, amounting to approximately RMB25.3 million (corresponding period of 2025: nil). Taking into account the effects of such non-recurring items, the operating loss for the six months ended 30 June 2026 was approximately RMB11.3 million, representing a decrease of approximately 117.5%, as compared with operating profit of approximately RMB64.4 million for the six months ended 30 June 2025.

SHARE OF RESULTS IN ASSOCIATES

The Group's share of losses in associates was approximately RMB3.0 million for the six months ended 30 June 2026 (corresponding period of 2025: gains of approximately RMB5.3 million).

FINANCE INCOME AND FINANCE COSTS

Finance income decreased by approximately 73.8% from approximately RMB10.3 million for the six months ended 30 June 2025 to approximately RMB2.7 million for the six months ended 30 June 2026.

Finance costs increased by approximately 40.7% from approximately RMB135,000 for the six months ended 30 June 2025 to approximately RMB190,000 for the six months ended 30 June 2026.

FINANCIAL LIABILITIES AT FVTPL

In 2020, Lifetech Shenzhen, a wholly-owned subsidiary of the Company, entered into a shareholders' agreement with certain independent third parties ("Series A Agreement"); in 2023 entered into another shareholders' agreement with certain independent third parties ("Series B Agreement"), and in June 2026 entered into another shareholders' agreement with certain independent third parties ("Series C Agreement") for issuance of shares of Biotyx Medical (Shenzhen) Co., Ltd. (元心科技(深圳)有限公司) ("Biotyx Medical"), a subsidiary of Lifetech Shenzhen. Pursuant to the above mentioned Series A, Series B and Series C Agreements, if Biotyx Medical is unable to meet certain specified conditions under agreed timeframe, some holders of these shares will have the right to require Biotyx Medical to redeem all of their shares at the predetermined consideration. Accordingly, such shares are classified as a financial liability.

The fair value change in relation to the financial liabilities for the six months ended 30 June 2026 is insignificant.

The fair value of financial liabilities at FVTPL as at 30 June 2026 amounted to approximately RMB576.8 million (31 December 2025: approximately RMB576.8 million).

Additional information is set out in Note 19 to the condensed consolidated financial statements in this interim report.

INCOME TAX

Income tax decreased from approximately RMB38.0 million for the six months ended 30 June 2025 to approximately RMB36.5 million for the six months ended 30 June 2026, which was mainly due to decreased assessable income.

NET PROFIT AND LOSS

Net profit attributable to owners of the Company for the six months ended 30 June 2026, excluding certain non-recurring items as set out below, was approximately RMB114.8 million as compared with the net profit amounting to approximately RMB238.5 million for the six months ended 30 June 2025, representing a decrease of approximately 51.9%. The decrease was mainly due to (i) a decrease in revenue, which amounted to approximately RMB75.9 million; and (ii) a decrease in net exchange gains, which amounted to approximately RMB56.8 million (net exchange losses of approximately RMB32.8 million for the six months ended 30 June 2026, as compared with net exchange gains of approximately RMB24.0 million in the corresponding period of 2025).

The above-mentioned non-recurring items include (i) the other losses arising from financial assets at FVTPL of approximately RMB0.8 million for the six months ended 30 June 2026 (corresponding period of 2025: gains of approximately RMB9.9 million); (ii) the share-based payment expenses of approximately RMB123.1 million for the six months ended 30 June 2026 (corresponding period of 2025: approximately RMB193.5 million); and (iii) the transaction expenses in connection with a proposed transaction involving the conditional acquisition of equity interest in Starway and the issue of convertible bonds, which the Board has resolved not to proceed with, amounting to approximately RMB25.3 million (corresponding period of 2025: nil). Taking into account the effects of such non-recurring items, the net loss attributable to owners of the Company for the six months ended 30 June 2026 was approximately RMB34.3 million, representing a decrease of approximately 162.3% as compared with net profit of approximately RMB55.1 million for the six months ended 30 June 2025.

EQUITY INSTRUMENTS AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME ("FVTOCI")

On 21 September 2022, the Group entered into a subscription agreement with Jenscare Scientific Co., Ltd. (寧波健世科技股份有限公司) ("Jenscare Scientific") pursuant to which the Group agreed to subscribe for shares of Jenscare Scientific upon its initial public offering, as a cornerstone investor, for an aggregate consideration of USD20.0 million (equivalent to approximately RMB143.9 million) in cash with the price of HKD27.8 per share. The fair value of the equity security in the listed entity is determined based on the closing prices quoted in active markets. They are accounted for using their fair values based on quoted market prices. The fair value of this investment as at 30 June 2026 amounted to approximately RMB35.6 million (31 December 2025: approximately RMB45.4 million), representing approximately 0.7% of the Company's total assets (31 December 2025: approximately 0.9%).

The unrealised foreign exchange losses in equity instruments at FVTOCI were approximately RMB1.7 million for the six months ended 30 June 2026 (corresponding period of 2025: losses of approximately RMB0.7 million), and the losses from changes in fair value of equity instruments at FVTOCI were approximately RMB8.1 million (corresponding period of 2025: gains of approximately RMB27.0 million).

Jenscare Scientific is a medical device company dedicated to the development of interventional products for the treatment of structural heart diseases. Established in 2011, it has developed a series of treatment solutions targeting different types of structural heart diseases, including tricuspid valve diseases, aortic valve diseases, mitral valve diseases and heart failure. The shares of Jenscare Scientific are listed on The Stock Exchange of Hong Kong Limited (the "Stock Exchange") (stock code: 9877). The Group held 5,646,600 H shares in Jenscare Scientific, representing approximately 1.8% of its total issued share capital as at 30 June 2026.

The investment is classified as equity instruments at FVTOCI in accordance with IFRS 9. Additional information in relation to the investment is set out in Note 14 to the condensed consolidated financial statements in this interim report. In the opinion of the Directors, the above investment is held for long-term strategic investment purposes and, as such, the above investment is classified as non-current asset.

LIQUIDITY AND FINANCIAL RESOURCES

During the six months ended 30 June 2026, the Group mainly financed its operations with its own working capital.

The Group recorded total current assets of approximately RMB2,070.3 million as at 30 June 2026 (31 December 2025: approximately RMB2,325.1 million) and total current liabilities of approximately RMB844.8 million as at 30 June 2026 (31 December 2025: approximately RMB1,479.4 million). As at 30 June 2026, the total current liabilities of the Group primarily included trade and other payables amounting to approximately RMB788.9 million (31 December 2025: approximately RMB841.1 million). Other payables primarily included accrued expenses of approximately RMB161.0 million (31 December 2025: approximately RMB153.2 million) primarily in relation to clinical expenses and exhibition expenses, as well as accrued payroll and bonus of approximately RMB87.6 million (31 December 2025: approximately RMB109.3 million).

Trade receivables in terms of debtor turnover days was 43 days (31 December 2025: 39 days), and trade payables in terms of creditor turnover days was 115 days (31 December 2025: 74 days).

The current ratio (calculated by dividing the total current assets by the total current liabilities) of the Group was approximately 2.45 as at 30 June 2026 (31 December 2025: approximately 1.57).

BORROWINGS

On 18 March 2026, Biotyx Medical, acting as the borrower, entered into a loan agreement with Bank of China Co., Ltd. Shenzhen Longhua Sub-branch (the "Lender"), pursuant to which the Lender agreed to lend a loan in the amount of RMB5.0 million to Biotyx Medical for a term of twelve months at interest rate of 2.8%.

As at 30 June 2026, the bank borrowing was RMB5.0 million (31 December 2025: nil) and the interest incurred therefrom was approximately RMB0.04 million for the six months ended 30 June 2026 (corresponding period of 2025: nil) which was recognised as finance costs.

CASH AND CASH EQUIVALENTS

As at 30 June 2026, the Group's cash and cash equivalents were approximately RMB953.8 million, representing an increase of approximately 32.6% from approximately RMB719.3 million as at 31 December 2025. The cash and cash equivalents of the Group were mainly denominated in Renminbi, US dollars and Euros.

GEARING RATIO

As at 30 June 2026, the gearing ratio of the Group (calculated based on the ratio of total bank borrowings to total equity) was approximately 0.2% (31 December 2025: zero).

CAPITAL STRUCTURE

Total equity attributable to equity holders of the Company amounted to approximately RMB3,319.4 million as at 30 June 2026 as compared with approximately RMB3,512.6 million as at 31 December 2025.

TREASURY POLICY

The Directors will continue to follow a prudent policy in managing the Group's financial resources such as cash, with the objective of maintaining a strong and healthy liquidity position to ensure that the Group is well-placed to seize future growth opportunities whenever such opportunities arise.

PROPERTY HELD

On 26 June 2019, Dongguan LifeTech Medical Co., Ltd. (東莞市先健醫療有限公司) ("Dongguan LifeTech"), a wholly-owned subsidiary of the Company entered into a land use right transfer contract with the Dongguan Natural Resources Bureau (東莞市自然資源局) for the acquisition of land use right of a land which has a site area of 43,604 square meters located at the southeast of the intersection of South 1 Road and South 8 Road in eastern Songshan Lake, Dongguan, Guangdong, the People's Republic of China ("PRC") (the "Land"). The land use right is wholly owned by the Group which was acquired at a total consideration of approximately RMB43.6 million.

On 24 April 2020, Dongguan LifeTech entered into a construction contract with China Construction Second Engineering Bureau Limited for the construction of an industrial park above the Land. The industrial park covers a total site area of approximately 43,604 square meters and can cater for the Group's day-to-day business and operational needs in Dongguan and nearby regions. The contract price for the construction works is up to a maximum aggregate amount of RMB620.0 million. The construction contract was approved by independent shareholders by way of poll at the extraordinary general meeting ("EGM") of the Company held on 30 June 2020. For further details and information, please refer to the Company's announcements dated 26 June 2019, 24 April 2020 and 30 June 2020 and the circular dated 9 June 2020.

In May 2023, the Company had obtained property ownership certificates of all buildings and basements. As at 30 June 2026, a portion of the total gross floor area of the industrial park has been allocated for the Company's own operations and external tenant leasing, with the remaining area reserved for future allocation.

MATERIAL ACQUISITIONS AND DISPOSALS OF SUBSIDIARIES, ASSOCIATES AND JOINT VENTURES

On 22 May 2026, the Company entered into a framework agreement with AUT-VII HK Holdings Limited ("AUT-VII HK"), pursuant to which the Company has conditionally agreed to acquire, and AUT-VII HK has conditionally agreed to sell, approximately 96.46% of the equity interest in Starway. On 20 July 2026, the Board has resolved not to proceed with the proposed acquisition of Starway.

Save as disclosed above, there were no other material acquisitions and disposals of subsidiaries, associates and joint ventures during the six months ended 30 June 2026.

SIGNIFICANT INVESTMENTS AND FUTURE PLANS FOR MATERIAL INVESTMENTS OR CAPITAL ASSETS

Save as disclosed in this interim report, there were no significant investments held by the Company with a value greater than 5% of its total assets as at 30 June 2026, nor was there any plan authorised by the Board for other material investments or additions of capital assets as at the date of this interim report.

The Group's investment strategy for significant investments is to identify investment opportunities with growth potential within the healthcare industry and seek opportunities for strategic cooperation. We hold our investments in equity instruments. Our investment objective is to form long-term strategic partnerships with companies in the medical industry with the potential of enriching our product lines and expanding our business scale, thereby maximising shareholders' interests and value.

CONTINGENT LIABILITIES

The Group did not have any significant contingent liabilities as at 30 June 2026.

FINANCIAL INSTRUMENT

As at 30 June 2026, the Group did not have any outstanding hedge contracts or financial derivative instruments.

CAPITAL EXPENDITURE

During the six months ended 30 June 2026, the capital expenditure of the Group for property, plant and equipment, construction in progress, intangible assets, right-of-use assets and deposits for property, plant and equipment amounted to approximately RMB50.5 million (corresponding period of 2025: approximately RMB56.7 million).

FOREIGN EXCHANGE EXPOSURE

During the six months ended 30 June 2026, the Group primarily conducted its operations in both Asia and Europe. The revenue generated from Asia (excluding China's mainland) and Europe accounted for approximately 10.3% and 12.6%, respectively, of the Group's total revenue for the six months ended 30 June 2026 (corresponding period of 2025: approximately 11.4% and 11.0%, respectively). The operational results and financial condition of the Group may be affected by fluctuations in exchange rates involving the currencies used in its business transactions.

Although the Group did not implement any hedging strategies to mitigate this exposure during the Reporting Period, the management closely monitored foreign currency exposure to maintain net exposure at an acceptable level. The Group expects that exchange rate fluctuations will not have a material adverse effect on its operations in the foreseeable future. However, the Group will consider hedging significant foreign currency exposure should the need arise.

CHARGES ON GROUP ASSETS

As at 30 June 2026, the Group did not have any charges on its assets.

CAPITAL COMMITMENT

As at 30 June 2026, the Group's capital expenditure contracted for but not provided in the condensed consolidated financial statements amounted to approximately RMB3.4 million (31 December 2025: approximately RMB15.8 million).

SEGMENT INFORMATION

During the six months ended 30 June 2026, the revenue of the Group was principally generated from the structural heart diseases business, the peripheral vascular diseases business and the cardiac pacing and electrophysiology business. An aging population, urbanisation and the continuous improvement of health awareness by the public, are all factors which contribute to the steady growth of the healthcare industry. These trends, along with our R&D efforts, suggest that there will be an increased demand for our products in the future, thus leading to business growth.

STRUCTURAL HEART DISEASES BUSINESS

The Company has developed four generations of congenital heart diseases occluders to satisfy various patients' needs, and to achieve differentiated marketing strategies. At the same time, we continue to upgrade the LAA occluder to meet the growing treatment demand with innovative technology. Driven by a large number of patients with atrial fibrillation around the world, the global market for the LAA occluder is expected to keep growing in the future.

PERIPHERAL VASCULAR DISEASES BUSINESS

The Company provides patients with technology-leading systemic and comprehensive interventional medical devices treatment solutions of peripheral vascular diseases. Among those products, the market shares of vena cava filters and stent grafts occupy a leading position in the domestic market. An aging population, increase in diseases detection rate and expansion of product applications are factors that would help drive the growth of market demand for these products.

CARDIAC PACING AND ELECTROPHYSIOLOGY BUSINESS

The Company offers innovative solutions for the diagnosis and treatment of cardiac arrhythmias.

Please refer to the paragraph headed "Financial Review – Revenue" above for the financial performance of these business segments. Financial information related to these aspects is presented in Note 4 to the condensed consolidated financial statements in this interim report.

EMPLOYEES AND REMUNERATION POLICY

As at 30 June 2026, the Group had 1,251 full-time employees (31 December 2025: 1,240) and three executive Directors (31 December 2025: five). Total staff costs, including share-based payment expenses, amounted to approximately RMB317.5 million for the six months ended 30 June 2026 (corresponding period of 2025: approximately RMB359.6 million), of which Directors' emoluments were approximately RMB96.1 million (corresponding period of 2025: approximately RMB22.3 million).

The employees of the Group who operate in the PRC are members of a state-managed retirement benefits scheme operated by the PRC government under which the employees are entitled to a monthly pension after retirement. The Group is required to contribute a certain percentage of employee's salaries to the retirement benefits scheme to fund the benefits. The only obligation of the Group with respect to the retirement benefits scheme is to make the aforementioned specified contributions. The Group operates the Mandatory Provident Fund Scheme for all qualifying employees in Hong Kong. Contributions to these schemes are expensed as incurred. During the six months ended 30 June 2026, the total cost paid or payable in relation to contributions to the retirement benefits scheme was approximately RMB18.9 million (corresponding period of 2025: approximately RMB18.7 million). Forfeited contributions (by the Group on behalf of the employees who leave the aforesaid schemes prior to vesting fully in such contributions) may not be used by the Group to reduce the existing level of contributions.

The Group's remuneration policies were determined with reference to the performance, qualification and working experience of individual employees, as well as the results of the Group and the market conditions. The benefits provided by the Group to its employees include discretionary bonus, transportation and meal subsidies, basic and group medical insurance, work injury insurance, unemployment insurance, annual physical examination, share options, etc. We have a fair and effective performance appraisal system and schemes designed to motivate and reward employees at all levels for their performance and achievements. The Company adopted a share option scheme on 22 October 2011, which was subsequently amended by unanimous written resolutions of the Board on 5 May 2015. On 17 September 2021, as the number of share options which may be granted under such share option scheme had reached its limit and would soon expire, the Company terminated such share option scheme and adopted a new share option scheme to provide incentives for employees of the Group and other eligible participants thereunder. The Company has adopted a share award scheme on 28 December 2018, which was subsequently amended by unanimous written resolutions of the Board on 29 April 2019. The Company also adopted another share award scheme on 3 March 2022.

Employees are the cornerstone of enterprise development, and the Group is committed to providing all employees with a safe and comfortable working environment, opportunities of equal employment, trainings and career development, such as orientation programmes for new employees, regulation-related trainings and position skills trainings. The Group has also established a labour union to safeguard the legitimate rights of its employees and to further promote the Group's sustainable, stable and healthy development.

THE 2020 PLACING

On 11 December 2020, the Company completed a placing of an aggregate of 287,320,000 new ordinary shares of the Company, with an aggregate nominal value of USD359.15, at a placing price of HKD3.2368 per share pursuant to a placing agreement dated 4 December 2020 (the "2020 Placing").

Pursuant to the 2020 Placing, an aggregate of 287,320,000 new ordinary shares, representing approximately 6.21% of the issued share capital of the Company as enlarged by the allotment and issue of the new shares immediately after the completion of the 2020 Placing, have been successfully placed to not less than six placees who and whose ultimate beneficial owner(s), to the best of the knowledge, information and belief of the Directors having made all reasonable enquiries, are independent of the Company. None of the placees and their respective ultimate beneficial owners have become a substantial shareholder (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules")) of the Company as a result of the placing.

The placing price of HKD3.2368 per placing share represents:

(i) a discount of approximately 11.6% to the closing price of HKD3.660 per share of the Company as quoted on the Stock Exchange on 3 December 2020, being the trading day prior to the date of the placing agreement;

(ii) a discount of approximately 9.3% to the average closing price of approximately HKD3.570 per share of the Company as quoted on the Stock Exchange for the five consecutive trading days immediately prior to the date of the placing agreement; and

(iii) a discount of approximately 2.3% to the average closing price of approximately HKD3.313 per share of the Company as quoted on the Stock Exchange for the ten consecutive trading days immediately prior to the date of the placing agreement.

The net placing price (after deducting the costs and expenses incurred for the 2020 Placing) was approximately HKD3.2366 per placing share. The net proceeds raised from the 2020 Placing were approximately HKD930.0 million.

As at 30 June 2026, approximately HKD380.6 million brought forward from the net proceeds received by the Company from the 2020 Placing remained unutilised.

As at 30 June 2026, the details and usage of the proceeds from the 2020 Placing were as follows:

Intended use of proceeds	Approximate allocation of net proceeds as previously disclosed (HKD in million)	Approximate amount of net proceeds unutilised as at 31 December 2025 (HKD in million)	Approximate utilisation of proceeds during the six months ended 30 June 2026 (HKD in million)	Approximate amount of net proceeds unutilised as at 30 June 2026 (HKD in million)	Expected timeline for utilisation of unutilised proceeds
Repayment of certain bank borrowings of the Group	406.0	—	—	—	Fully utilised
Funding potential business development involving a new overseas clinical project	465.0	384.9	4.3	380.6	To be applied in the second half of 2026 (HKD20.0 million) and 2027 (HKD360.6 million) subject to adjustments (if any)
General working capital of the Group	59.0	—	—	—	Fully utilised
Total	**930.0**	**384.9**	**4.3**	**380.6**	

Approximately HKD4.3 million of the net proceeds of the 2020 Placing had been utilised during the six months ended 30 June 2026 in accordance with the intended use of proceeds. There has been no change in the intended use of net proceeds. The unutilised net proceeds from the 2020 Placing would be brought forward to the next financial period/year and will be gradually utilised in accordance with the above intended purposes.

The Directors consider that the 2020 Placing represented an opportunity to raise capital while broadening its capital and shareholder base. The Directors were of the view that the 2020 Placing would strengthen the financial position of the Company and provide working capital to the Company.

For further details, please refer to the Company's announcements dated 4 December 2020 and 11 December 2020.

EVENTS AFTER THE REPORTING PERIOD

Reference is made to the Company's announcement dated 22 May 2026 regarding a transaction involving the proposed acquisition of equity interest in Starway and the proposed issue of convertible bonds. Following the publication of the announcement, the Company negotiated with AUT-VII HK on the definitive transaction documents. As the two parties were unable to reach a consensus, after prudent consideration, the Board resolved not to proceed with the major transaction on 20 July 2026, as disclosed in the Company's announcement dated 20 July 2026.

Reference is made to the Company's announcement dated 12 August 2026. Mr. FANG Yu, an executive Director, has been appointed as an authorised representative of the Company with effect from 12 August 2026.

Save as disclosed above, there were no other significant events affecting the Group after 30 June 2026.

FUTURE PROSPECTS

The global medical device industry continues to present significant growth opportunities, driven by demographic shifts, technological advancements, and increasing healthcare demands. Although the expansion of the coverage of China's centralized procurement policies has exerted pricing pressure on certain medical device products, it has also accelerated industry consolidation, prompting companies to place greater emphasis on innovation and differentiated competition. Leveraging strong R&D capabilities, a diversified product portfolio, and a growing global presence, the Company has established a resilient competitive advantage, enabling us to proactively capture industry opportunities and drive sustained and stable business growth. Despite the volatility of the internal and external environment during the Reporting Period, which had certain impact on the Group's short-term financial performance, the Group's core business remained stable, with continuous optimization of its product sales mix and orderly progress across all work streams, laying a solid foundation for sustainable growth in the future.

Looking ahead, the Company will continue to focus on advancing its robust R&D pipeline, accelerating product commercialization both domestically and internationally, and expanding its global market presence. We remain committed to disciplined capital allocation and operational efficiency to navigate the evolving market dynamics. The Company will continue to invest in innovation and technology to address unmet clinical needs, while strengthening its competitive position in the global medical device industry.

The Company is confident in its ability to navigate both challenges and opportunities in the evolving healthcare landscape. By staying true to our core strengths in innovation and execution, we are well-positioned to deliver sustainable long-term growth and reinforce our leadership in the global medical device industry. We remain committed to creating value for patients, healthcare providers, and shareholders through our continued focus on technological advancement and operational excellence.

CORPORATE GOVERNANCE HIGHLIGHTS

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

The Company is committed to achieving high standards of corporate governance to safeguard the interests of its shareholders (the "Shareholders") and enhance its corporate value. The Company has applied the principles as set out in the Corporate Governance Code (the "CG Code") contained in Appendix C1 to the Listing Rules as its own code of corporate governance and confirms that it has complied with all code provisions of the CG Code during the six months ended 30 June 2026, save for the deviation from code provision C.2.1 of the CG Code as mentioned below.

According to code provision C.2.1 of the CG Code, the roles of the Chairman and Chief Executive Officer should be separate and should not be performed by the same individual. Subsequent to the resignation of former Chief Executive Officer of the Company, Mr. XIE Yuehui, Chairman of the Board, has been appointed to act as the Chief Executive Officer of the Company on 2 March 2015. Accordingly, the roles of the Chairman of the Board and the Chief Executive Officer are performed by the same individual. Although the dual roles of the Chairman and Chief Executive Officer is a deviation from the code provision C.2.1 of the CG Code, the Board believes that vesting the roles of both Chairman and Chief Executive Officer in an experienced and qualified person such as Mr. XIE Yuehui provides the Company with strong and consistent leadership while allowing for effective and efficient planning and implementation of business decisions and strategies.

The Board reviews the corporate governance structure and practices from time to time and shall make necessary arrangements when the Board considers appropriate.

THE BOARD

The Board currently comprises six Directors, including three executive Directors, namely Mr. XIE Yuehui, Ms. WU Liping and Mr. FANG Yu; and three independent non-executive Directors with at least one independent non-executive Director possessing appropriate professional qualifications, or accounting or related financial management expertise, namely Mr. ZHOU Luming, Ms. CHEN Dongxia and Mr. JIANG Feng.

Further to the Company's announcement on 18 June 2026, Mr. JIANG Feng, an independent non-executive Director, has been appointed as a member of the audit committee and remuneration committee of the Company respectively.

MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the "Model Code") as set out in Appendix C3 to the Listing Rules as its own code of conduct for dealing in securities of the Company by the Directors on terms no less exacting than the required standard set out in the Model Code.

Having made specific enquiries with all the Directors, the Company confirmed that all members of the Board complied with the Model Code during the six months ended 30 June 2026.

Senior management, executives and staff members who, because of their offices in the Company, are likely to possess inside information, have also been requested to comply with the provisions of the Model Code. No incident of non-compliance with the Model Code by such employees was noted by the Company during the six months ended 30 June 2026.

AUDIT COMMITTEE AND REVIEW OF INTERIM REPORT

The Board has established an audit committee (the "Audit Committee") in accordance with the corporate governance requirements of listed companies of the Stock Exchange. As at the date of this interim report, the Audit Committee consists of three members, all of whom are independent non-executive Directors, namely Ms. CHEN Dongxia who possesses appropriate professional qualifications to serve as its Chairlady, Mr. ZHOU Luming and Mr. JIANG Feng.

The Group's unaudited interim report for the six months ended 30 June 2026 and accounting principles have been reviewed and discussed by the Audit Committee, which was of the opinion that the preparation of such results was in compliance with the relevant accounting standards, the Listing Rules and the applicable legal requirements, and that adequate disclosure has been made.

DIRECTORS' AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY AND ITS ASSOCIATED CORPORATIONS

As at 30 June 2026, the interests and short positions of the Directors and chief executives of the Company in the shares, underlying shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (the "SFO")) which were required (a) to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they are taken or deemed to have under such provisions of the SFO), or (b) to be and were entered into the register required to be kept by the Company pursuant to Section 352 of the SFO, or (c) as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code were as follows:

LONG POSITIONS IN SHARES AND UNDERLYING SHARES OF THE COMPANY

Name of Directors	Capacity	Number of share(s) of the Company ("Share(s)") (long position)	Approximate percentage of shareholding
Mr. XIE Yuehui	Interest of controlled corporation and beneficial owner	468,794,928 (Note 1)	10.12%
Ms. WU Liping	Beneficial owner	82,870,000 (Note 2)	1.79%
Mr. FANG Yu	Beneficial owner	65,700,000 (Note 3)	1.42%

Notes:

1. These interests represented:

   (a) 464,194,928 shares held by Xianjian Advanced Technology Limited, which is wholly owned by Mr. XIE Yuehui, the Chairman, Chief Executive Officer and executive Director; and

   (b) 4,600,000 options granted to Mr. XIE Yuehui on 24 January 2024, which were subject to certain vesting conditions pursuant to the Share Option Scheme of the Company, details of which are set out in the section headed "Share Option Scheme" in this interim report.

2. These interests represented:

   (a) 45,163,333 shares held by Ms. WU Liping, an executive Director;

   (b) 500,000 options granted to Ms. WU Liping on 31 March 2021, 6,290,000 options granted to Ms. WU Liping on 10 December 2021, and 16,250,000 options granted to Ms. WU Liping on 24 January 2024 respectively, which were subject to certain vesting conditions pursuant to the Previous Scheme and Share Option Scheme of the Company, details of which are set out in the section headed "Share Option Scheme" in this interim report; and

   (c) awards representing 22,000,000 shares were granted to Ms. WU Liping pursuant to the 2022 Share Award Scheme (as defined below). As at the date of this report, 14,666,667 shares remain outstanding.

3. These interests represented:

   (a) 37,333,333 shares held by Mr. FANG Yu, an executive Director;

   (b) 400,000 options granted to Mr. FANG Yu on 31 March 2021, 1,300,000 options granted to Mr. FANG Yu on 10 December 2021, and 16,000,000 options granted to Mr. FANG Yu on 24 January 2024 respectively, which were subject to certain vesting conditions pursuant to the Previous Scheme and Share Option Scheme of the Company, details of which are set out in the section headed "Share Option Scheme" in this interim report; and

   (c) awards representing 16,000,000 shares were granted to Mr. FANG Yu pursuant to the 2022 Share Award Scheme (as defined below). As at the date of this report, 10,666,667 shares remain outstanding.

Save as disclosed above, as at 30 June 2026, so far as is known to any Directors or chief executives of the Company, none of the Directors or chief executives of the Company had any interests or short positions in the shares, underlying shares and debentures of the Company or its associated corporations (within the meaning of Part XV of the SFO) which were required (a) to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have under such provisions of the SFO), or (b) to be entered in the register required to be kept by the Company pursuant to section 352 of the SFO, or (c) to be notified to the Company and the Stock Exchange pursuant to the Model Code.

SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES OF THE COMPANY

As at 30 June 2026, other than the interests of Directors or chief executives of the Company as disclosed under the section headed "DIRECTORS' AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY AND ITS ASSOCIATED CORPORATIONS" above, the interests and short positions of persons in the shares and underlying shares of the Company which would fall to be disclosed under the provisions of Divisions 2 and 3 of Part XV of the SFO as recorded in the register required to be kept by the Company under section 336 of the SFO, or who was, directly or indirectly, interested in 5% or more of the issued shares, were as follows:

LONG POSITIONS IN SHARES OF THE COMPANY

Name of Shareholders	Capacity	Number of Shares (long position)	Approximate percentage of shareholding
Xianjian Advanced Technology Limited (Note 1)	Beneficial owner	464,194,928	10.02%
Futu Trustee Limited (Note 2)	Trustee	386,458,337	8.34%
	Custodian (other than an exempt custodian interest)	21,979,998	0.47%

Notes:

1. The entire issued share capital of Xianjian Advanced Technology Limited is wholly owned by Mr. XIE Yuehui, the Chairman, Chief Executive Officer and an executive Director of the Company.

2. Futu Trustee Limited holds 21,979,998 shares as the custodian of the vested shares of the employees of the 2022 Share Award Scheme (as defined below) trust.

3. Based on the notices of disclosure of interest filed respectively by AUT-VII HK, AUT-VII Holdings Limited, AUT-II Holdings Limited, Hillhouse Investment Management V, L.P., Hillhouse Fund V, L.P. and Hillhouse Investment Management, Ltd., AUT-VII HK beneficially owns 860,427,720 unlisted shares of the Company by virtue of unlisted convertible instruments and is owned as to 100% by AUT-VII Holdings Limited, which is wholly owned by AUT-II Holdings Limited. AUT-II Holdings Limited is a wholly-owned subsidiary of Hillhouse Investment Management V, L.P., which is in turn majority held by Hillhouse Fund V, L.P., the investment manager of which is Hillhouse Investment Management, Ltd.. Accordingly, each of AUT-VII Holdings Limited, AUT-II Holdings Limited, Hillhouse Investment Management V, L.P., Hillhouse Fund V, L.P. and Hillhouse Investment Management, Ltd. is deemed to be interested in the 860,427,720 unlisted shares of the Company held by AUT-VII HK by virtue of the provisions of Part XV of the SFO.

   Reference is made to the announcement of the Company dated 22 May 2026 in relation to the proposed acquisition of approximately 96.46% equity interest in Starway and the issue of convertible bonds to AUT-VII HK as consideration therefor. As disclosed in the announcement of the Company dated 20 July 2026, the Board decided not to proceed with the proposed acquisition and the issue of convertible bonds. As such, no convertible bonds will be issued to AUT-VII HK.

Save as disclosed above, as at 30 June 2026, the Directors have not been notified by any person (other than the Directors or chief executives of the Company) who had interests or short positions in the shares or underlying shares as recorded in the register required to be kept pursuant to Section 336 of the SFO.

SHARE OPTION SCHEME

The previous share option scheme (the "Previous Scheme") adopted by the Company on 22 October 2011, which was amended by a unanimous written resolution of the Board on 5 May 2015, was terminated pursuant to an ordinary resolution passed by the shareholders at the EGM on 17 September 2021. A new share option scheme (the "Share Option Scheme") in place of the Previous Scheme was adopted by the Company with effect from 17 September 2021, which has a term of 10 years.

1. PURPOSE OF THE SHARE OPTION SCHEME

The purpose of the Share Option Scheme is to enable the Company to grant options to the Share Option Scheme Eligible Participants (as defined below) as incentives or rewards for their contribution to the growth of the Group and to provide the Group with a more flexible means to reward, remunerate, compensate and/or provide benefits to the Share Option Scheme Eligible Participants.

2. PARTICIPANTS OF THE SHARE OPTION SCHEME AND THE BASIS OF DETERMINING THE ELIGIBILITY OF THE PARTICIPANTS

The Board may at its discretion grant options to any full-time or part-time employees, Directors (including executive, non-executive or independent non-executive), any consultants or advisers (whether professional or otherwise), supplier, service provider, customer, business partner, shareholder, any person or entity that provides design, R&D or other technological support and any other group or classes of participants who have contributed or may contribute to the development and growth of our Company and/or any entity in which our Company holds an equity interest (collectively the "Share Option Scheme Eligible Participants").

3. MAXIMUM NUMBER OF SHARES

The total number of shares which may be issued upon exercise of all options to be granted under the Share Option Scheme and any other share option schemes of our Group is 462,929,240, being not more than 10% of the issued share capital of the Company as at 17 September 2021, adoption date of the Share Option Scheme. Any options lapsed in accordance with the terms of the Share Option Scheme or any other share option scheme of the Group shall not be counted for the purpose of calculating the Scheme Mandate Limit.

The maximum number of further share options that may be granted under the Share Option Scheme was 151,379,240 as at 1 January 2026, 30 June 2026 and as at the date of this interim report, representing approximately 3.27% of the number of total issued shares of the Company. No further share options may be granted under the Previous Scheme. There is no service provider sublimit under the Share Option Scheme.

4. MAXIMUM ENTITLEMENT OF EACH PARTICIPANT

Unless approved by the shareholders in the manner set out in the Share Option Scheme, the total number of shares issued and to be issued upon exercise of the options granted to each Share Option Scheme Eligible Participant (including both exercised and outstanding options under the Share Option Scheme) in any 12-month period must not exceed 1% of the issued share capital of the Company.

5. OFFER PERIOD AND AMOUNT PAYABLE FOR OPTIONS

An offer of grant of an option shall remain open for acceptance by the Share Option Scheme Eligible Participants concerned for such period as determined by the Board, which period shall not be more than fourteen (14) days from the date of the offer, provided that no such offer shall be open for acceptance after the tenth anniversary of 17 September 2021 or after the Share Option Scheme has been terminated in accordance with the provisions thereof. Upon acceptance of the offer, the grantee shall pay HKD1.00 to the Company by way of consideration for the grant and the date on which the option is offered shall be deemed to be the date of grant of the relevant option, except in determining the date of grant for the purpose of calculating the subscription price.

6. MINIMUM PERIOD FOR WHICH AN OPTION MUST BE HELD BEFORE IT CAN BE EXERCISED

There is no general requirement on the minimum period for which an option must be held or the performance targets which must be achieved before an option can be exercised under the terms of the Share Option Scheme. However, the Board may offer to grant any options subject to such terms and conditions in relation to the minimum period of the options to be held and/or the performance targets to be achieved before such options can be exercised as the Board may determine in its absolute discretion.

7. BASIS OF DETERMINING THE SUBSCRIPTION PRICE

The subscription price for shares in respect of any particular option granted under the Share Option Scheme shall be such price as the Board shall determine, provided that such price shall be at least the highest of:

(i) the closing price per share as stated in the Stock Exchange's daily quotation sheet on the date of offer of the option;

(ii) the average closing price per share as stated in the Stock Exchange's daily quotation sheets for the five (5) business days immediately preceding the date of offer of the option; and

(iii) the nominal value of a share.

8. REMAINING LIFE OF THE SHARE OPTION SCHEME

Subject to the fulfilment of the conditions of the Share Option Scheme and the earlier termination by shareholders' resolution in general meeting or the Board, the Share Option Scheme shall be valid and effective for a period of ten (10) years commencing from 17 September 2021, after which period no further options will be offered or granted but the provisions of the Share Option Scheme shall remain in full force and effect in all other respects with respect to options granted during the life of the Share Option Scheme. The remaining life of the Share Option Scheme is approximately five years and three months as at 30 June 2026.

The table below sets out details of the outstanding share options granted to the Directors and other grantees under the Previous Scheme and movements during the period from 1 January 2026 to 30 June 2026:

					Number of shares					
Name	Date of grant	Vesting schedule	Option period	Exercise price	Granted on the date of grant	Outstanding as at 1 January 2026	Exercised during the six months ended 30 June 2026	Closing price (weighted average) of the shares of the Company immediately before the dates on which the options were exercised	Lapsed/ cancelled during the six months ended 30 June 2026	Outstanding as at 30 June 2026
Directors										
Ms. WU Liping	31 March 2021	30%, 30%, 40% of options on 31 March 2022, 2023 and 2024, respectively	10 years from the date of grant	HKD3.570	500,000	500,000	–	–	–	500,000
Sub-total					500,000	500,000	–	–	–	500,000
Mr. FANG Yu	31 March 2021	30%, 30%, 40% of options on 31 March 2022, 2023 and 2024, respectively	10 years from the date of grant	HKD3.570	400,000	400,000	–	–	–	400,000
Sub-total					400,000	400,000	–	–	–	400,000
Ms. FENG Xiaoling (resigned from the directorship on 22 May 2026)	31 March 2021	30%, 30%, 40% of options on 31 March 2022, 2023 and 2024, respectively	10 years from the date of grant	HKD3.570	800,000	800,000	–	–	–	800,000
Sub-total					800,000	800,000	–	–	–	800,000
Other Grantees										
Employees	31 March 2021	30%, 30%, 40% of options on 31 March 2022, 2023 and 2024, respectively	10 years from the date of grant	HKD3.570	31,620,000	23,890,000 (Note 1)	–	–	(300,000)	23,590,000 (Note 2)
Sub-total					31,620,000	23,890,000	–	–	(300,000)	23,590,000
Total					33,320,000	25,590,000	–	–	(300,000)	25,290,000

Note 1: The 23,890,000 outstanding share options as at 1 January 2026 were held by 89 grantees who were employees of the Group.

Note 2: The 23,590,000 outstanding share options as at 30 June 2026 were held by 87 grantees who were employees of the Group.

No share options were granted under the Previous Scheme during the period from 1 January 2026 to 30 June 2026 and 25,290,000 share options remained outstanding under the Previous Scheme, which represents approximately 0.55% of the total number of issued shares of the Company as at 30 June 2026.

The table below sets out details of the outstanding share options granted to the Directors and other grantees under the Share Option Scheme and movements during the period of 1 January 2026 to 30 June 2026:

					Number of shares					
Name	Date of grant	Vesting schedule	Option period	Exercise price	Granted on the date of grant	Outstanding as at 1 January 2026	Exercised during the six months ended 30 June 2026	Closing price (weighted average) of the shares of the Company immediately before the dates on which the options were exercised	Lapsed/ cancelled during the six months ended 30 June 2026	Outstanding as at 30 June 2026
Directors/Chief Executives										
Mr. XIE Yuehui	24 January 2024	15%, 15%, 20%, 25% and 25% upon completion of the Group's annual performance assessment of 2024, 2025, 2026, 2027 and 2028, respectively	10 years from the date of grant	HKD1.950	4,600,000	4,600,000	–	–	–	4,600,000
Sub-total					4,600,000	4,600,000	–	–	–	4,600,000
Mr. LIU Jianxiong (resigned from the directorship on 22 May 2026)	24 January 2024	15%, 15%, 20%, 25% and 25% upon completion of the Group's annual performance assessment of 2024, 2025, 2026, 2027 and 2028, respectively	10 years from the date of grant	HKD1.950	36,000,000	36,000,000	–	–	–	36,000,000
Sub-total					36,000,000	36,000,000	–	–	–	36,000,000
Ms. WU Liping	10 December 2021	10%, 15%, 20%, 25% and 30% upon completion of the Group's annual performance assessment of 2022, 2023, 2024, 2025 and 2026, respectively	10 years from the date of grant	HKD3.836	6,290,000	6,290,000	–	–	–	6,290,000
Ms. WU Liping	24 January 2024	15%, 15%, 20%, 25% and 25% upon completion of the Group's annual performance assessment of 2024, 2025, 2026, 2027 and 2028, respectively	10 years from the date of grant	HKD1.950	16,250,000	16,250,000	–	–	–	16,250,000
Sub-total					22,540,000	22,540,000	–	–	–	22,540,000

Name	Date of grant	Vesting schedule	Option period	Exercise price	Number of shares: Granted on the date of grant	Outstanding as at 1 January 2026	Exercised during the six months ended 30 June 2026	Closing price (weighted average) of the shares of the Company immediately before the dates on which the options were exercised	Lapsed/ cancelled during the six months ended 30 June 2026	Outstanding as at 30 June 2026
Mr. FANG Yu	10 December 2021	10%, 15%, 20%, 25% and 30% upon completion of the Group's annual performance assessment of 2022, 2023, 2024, 2025 and 2026, respectively	10 years from the date of grant	HKD3.836	1,300,000	1,300,000	–	–	–	1,300,000
Mr. FANG Yu	24 January 2024	15%, 15%, 20%, 25% and 25% upon completion of the Group's annual performance assessment of 2024, 2025, 2026, 2027 and 2028, respectively	10 years from the date of grant	HKD1.950	16,000,000	16,000,000	–	–	–	16,000,000
Sub-total					17,300,000	17,300,000	–	–	–	17,300,000
Ms. FENG Xiaoling (resigned from the directorship on 22 May 2026)	10 December 2021	10%, 15%, 20%, 25% and 30% upon completion of the Group's annual performance assessment of 2022, 2023, 2024, 2025 and 2026, respectively	10 years from the date of grant	HKD3.836	1,300,000	1,300,000	–	–	–	1,300,000
Ms. FENG Xiaoling (resigned from the directorship on 22 May 2026)	24 January 2024	15%, 15%, 20%, 25% and 25% upon completion of the Group's annual performance assessment of 2024, 2025, 2026, 2027 and 2028, respectively	10 years from the date of grant	HKD1.950	16,000,000	16,000,000	–	–	–	16,000,000
Sub-total					17,300,000	17,300,000	–	–	–	17,300,000

Name	Date of grant	Vesting schedule	Option period	Exercise price	Number of shares: Granted on the date of grant	Outstanding as at 1 January 2026	Exercised during the six months ended 30 June 2026	Closing price (weighted average) of the shares of the Company immediately before the dates on which the options were exercised	Lapsed/ cancelled during the six months ended 30 June 2026	Outstanding as at 30 June 2026
Other Grantees										
Employees	12 November 2021	10%, 15%, 20%, 25% and 30% upon completion of the Group's annual performance assessment of 2022, 2023, 2024, 2025 and 2026, respectively	10 years from the date of grant	HKD3.590	101,800,000	82,755,000	–	–	(510,000)	82,245,000 (Note 1)
Employees	10 December 2021	10%, 15%, 20%, 25% and 30% upon completion of the Group's annual performance assessment of 2022, 2023, 2024, 2025 and 2026, respectively	10 years from the date of grant	HKD3.836	2,110,000	1,380,000	–	–	–	1,380,000 (Note 2)
Consultants	10 December 2021	10%, 15%, 20%, 25% and 30% upon completion of the Group's annual performance assessment of 2022, 2023, 2024, 2025 and 2026, respectively	10 years from the date of grant	HKD3.836	24,000,000	24,000,000	–	–	–	24,000,000 (Note 3)
Employees	24 January 2024	15%, 15%, 20%, 25% and 25% upon completion of the Group's annual performance assessment of 2024, 2025, 2026, 2027 and 2028, respectively	10 years from the date of grant	HKD1.950	85,900,000	78,013,750	–	–	(425,000)	77,588,750 (Note 4)
Sub-total					213,810,000	186,148,750	–	–	(935,000)	185,213,750
Total					311,550,000	283,888,750	–	–	(935,000)	282,953,750

Note 1: The 82,245,000 outstanding share options as at 30 June 2026 were held by 125 grantees who are employees of the Group (who are neither a director, chief executive or substantial shareholder of the Company nor their respective associates).

Note 2: The 1,380,000 outstanding share options as at 30 June 2026 were held by 16 grantees who are employees of the Group (who are neither a director, chief executive or substantial shareholder of the Company nor their respective associates).

Note 3: The 24,000,000 outstanding share options as at 30 June 2026 were held by 5 grantees who are consultants of the Group (who are neither a director, chief executive or substantial shareholder of the Company nor their respective associates). Among these grantees, there were two legal advisors, a medical advisor and an investment advisor who had options granted during the 12-month period exceeding 0.1% of the total number of issued shares as at the date of grant. Each of the above mentioned 4 advisors was granted 5,000,000 share options each on 10 December 2021, representing 0.11% (i.e. more than 0.1%) of the total number of issued shares as at the date of grant.

Note 4: The 77,588,750 outstanding share options as at 30 June 2026 were held by 191 grantees who are employees of the Group (who are neither a director, chief executive or substantial shareholder of the Company nor their respective associates).

As at 30 June 2026, 282,953,750 share options remained outstanding under the Share Option Scheme. The numbers of options available for further grant under the Share Option Scheme as at 1 January 2026 and 30 June 2026 were both 151,379,240.

As at 30 June 2026, there was no participant with share options granted in excess of the 1% individual limit as defined under Chapter 17 of the Listing Rules.

VALUE OF SHARE OPTIONS

The Binomial Model had been used to estimate the fair value of the share options. The model involves the construction of a binomial lattice which represents different possible paths that might be followed by the stock price over the life of the options. In developing the binomial lattice, the life of the options is divided into various time steps. In each time step there is a binomial stock price movement. The main inputs to the model include the share price of the Company, exercise price, exercise multiple, risk-free rate, expected volatility, dividend yield and expected life of the options.

VALUE OF SHARE OPTIONS GRANTED ON 31 MARCH 2021

The fair value of the share options granted on 31 March 2021 was HKD53.0 million, and the specific parameters were selected by an independent qualified professional valuer as follows:

a. Stock price: HKD3.570 per share (being the closing price of HKD3.570 per share as of the grant date)

b. Exercise price: HKD3.570 per share (being the highest price of (i) the closing price of HKD3.570 per share as stated in the daily quotation sheets issued by the Stock Exchange on the grant date; (ii) the average closing price of HKD3.404 per share as stated in the daily quotation sheets issued by the Stock Exchange for the five (5) business days immediately preceding the grant date; and (iii) the nominal value of a share)

c. Expected volatility: 51.35% (based on the historical share price volatility of comparable companies in the relevant period)

d. Risk-free interest rate: 1.33% (based on the yields of HKD Hong Kong Sovereign Curve with respective tenors as at the grant date)

VALUE OF SHARE OPTIONS GRANTED ON 12 NOVEMBER 2021

The fair value of the share options granted on 12 November 2021 was HKD188.4 million, and the specific parameters were selected by an independent qualified professional valuer as follows:

a. Stock price: HKD3.590 per share (being the closing price of HKD3.590 per share as of the grant date)

b. Exercise price: HKD3.590 per share (being the highest price of (i) the closing price of HKD3.590 per share as stated in the daily quotation sheets issued by the Stock Exchange on the grant date; (ii) the average closing price of HKD3.546 per share as stated in the daily quotation sheets issued by the Stock Exchange for the five (5) business days immediately preceding the grant date; and (iii) the nominal value of a share)

c. Expected volatility: 51.53% (based on the historical share price volatility of comparable companies in the relevant period)

d. Risk-free interest rate: 1.39% (based on the yields of HKD Hong Kong Sovereign Curve with relevant tenors as at the grant date)

VALUE OF SHARE OPTIONS GRANTED ON 10 DECEMBER 2021

The fair value of the share options granted on 10 December 2021 was HKD67.9 million, and the specific parameters were selected by an independent qualified professional valuer as follows:

a. Stock price: HKD3.800 per share (being the closing price of HKD3.800 per share as of the grant date)

b. Exercise price: HKD3.836 per share (being the highest price of (i) the closing price of HKD3.800 per share as stated in the daily quotation sheets issued by the Stock Exchange on the grant date; (ii) the average closing price of HKD3.836 per share as stated in the daily quotation sheets issued by the Stock Exchange for the five (5) business days immediately preceding the grant date; and (iii) the nominal value of a share)

c. Expected volatility: 51.54% (based on the historical share price volatility of comparable companies in the relevant period)

d. Risk-free interest rate: 1.37% (based on the yields of HKD Hong Kong Sovereign Curve with relevant tenors as at the grant date)

VALUE OF SHARE OPTIONS GRANTED ON 24 JANUARY 2024

The fair value of the share options granted on 24 January 2024 was HKD172.9 million, and the specific parameters were selected by an independent qualified professional valuer as follows:

a. Stock price: HKD1.900 per share (being the closing price of HKD1.900 per share as of the grant date)

b. Exercise price: HKD1.950 per share (being the highest price of (i) the closing price of HKD1.900 per share as stated in the daily quotation sheets issued by the Stock Exchange on the grant date; (ii) the average closing price of HKD1.950 per share as stated in the daily quotation sheets issued by the Stock Exchange for the five (5) business days immediately preceding the grant date; and (iii) the nominal value of a share)

c. Expected volatility: 51.10% (based on the historical share price volatility of comparable companies in the relevant period)

d. Risk-free interest rate: 3.57% (based on the yields of HKD Hong Kong Sovereign Curve with relevant tenors as at the grant date)

SHARE AWARD SCHEME

2019 SHARE AWARD SCHEME

The Company adopted a share award scheme on 28 December 2018 which was subsequently amended by a unanimous written resolution of the Board on 29 April 2019 (the "2019 Share Award Scheme"). No new shares have been issued by the Company for the 2019 Share Award Scheme, as all the shares held under such scheme are existing shares.

On 29 September 2020, a total of 312,620,000 shares (the "2019 Granted Shares") have been vested to certain grantees. As at 30 June 2026, among the 2019 Granted Shares, 87,084,338 shares of which had been taken up by the grantees.

Under the 2019 Share Award Scheme, the Board shall not make any further grant of award such that the total number of shares granted under such scheme will exceed 10% of the total number of issued shares as of the date of adoption of such scheme (namely 28 December 2018). Since the adoption of the 2019 Share Award Scheme up to the date of this report, a total of 312,620,000 shares have been granted and vested under the 2019 Share Award Scheme, representing approximately 7.2% of the total number of issued shares of the Company as of the date of adoption of such scheme.

The Company adopted another share award scheme on 3 March 2022, which was amended and restated by the Board on 23 May 2025 and 13 February 2026, respectively (the "2022 Share Award Scheme"). No new shares have been issued by the Company for the 2022 Share Award Scheme, as all the shares held under such scheme are old shares. Upon adoption of the 2022 Share Award Scheme, the Board expected that no award would be further granted under the 2019 Share Award Scheme. As at 31 December 2025, the 2019 Share Award Scheme was retained for the purpose of continuing holding the remaining 2019 Granted Shares on the grantees' behalf. On 30 March 2026, such grantees irrevocably surrendered and foregone their stakes in such remaining 2019 Granted Shares (i.e. 225,535,662 shares) held by the 2019 Scheme Trustee under the 2019 Share Award Scheme. To facilitate administration, the Board resolved to transfer such shares from the 2019 Share Award Scheme to the 2022 Share Award Scheme to become part of the trust assets thereunder in accordance with the terms and conditions of the 2022 Share Award Scheme, and it is expected that the 2019 Share Award Scheme would be terminated accordingly upon the completion of such transfer.

1. OBJECTIVE OF THE 2019 SHARE AWARD SCHEME

The objectives of the 2019 Share Award Scheme are (i) to recognise and motivate the contributions by certain eligible participants and to incentivise them and retain them for the continual operation and development of the Group; (ii) to attract suitable personnel for further development of the Group; and (iii) to provide certain eligible participants with a direct economic interest in attaining a long-term relationship between the Group and certain eligible participants.

2. PARTICIPANTS OF THE 2019 SHARE AWARD SCHEME AND THE BASIS OF DETERMINING THE ELIGIBILITY OF THE PARTICIPANTS

The Board may at its discretion grant shares of the Company pursuant to the 2019 Share Award Scheme ("2019 Scheme Award Shares") to any employee and non-executive Director of the Company or any member of the Group who in the sole opinion of the Board will contribute or have contributed to any member of the Group (collectively the "2019 Scheme Selected Participants").

3. MAXIMUM NUMBER OF 2019 SCHEME AWARD SHARES

Pursuant to the rules of the 2019 Share Award Scheme, the Board shall not make any further grant of 2019 Scheme Award Shares such that the total number of shares granted under the 2019 Share Award Scheme will exceed 10% of the total number of issued shares as at 28 December 2018 (the "2019 SAS Adoption Date").

There is no maximum entitlement to 2019 Scheme Award Shares stipulated for a 2019 Scheme Selected Participant under the 2019 Share Award Scheme. As the Board does not expect to grant any new awards under the 2019 Share Award Scheme in light of the adoption of the 2022 Share Award Scheme, as at the date of this report, the Board has resolved to terminate the 2019 Share Award Scheme.

4. AMOUNT PAYABLE FOR THE 2019 SCHEME AWARD SHARES

An offer of grant of 2019 Scheme Award Shares shall remain open for acceptance by the 2019 Scheme Selected Participants concerned for ten (10) business days from the date of the offer. In order to receive the 2019 Scheme Award Shares, the grantee shall submit to the Company the documents stipulated under the scheme and pay to the Company the amount specified in the award notice, thereafter the Company will instruct the trustee under the scheme in writing to transfer the corresponding 2019 Scheme Award Shares to the relevant grantee. The purchase price of the 2019 Scheme Award Shares would be the average price paid by the trustee under the 2019 Share Award Scheme for such purchase or subscription of such shares.

5. VESTING PERIOD AND CONDITIONS

All 2019 Scheme Award Shares granted have been vested as at 30 June 2026.

6. REMAINING LIFE OF THE 2019 SHARE AWARD SCHEME

The 2019 Share Award Scheme shall be valid and effective for a term of ten (10) years commencing on the 2019 SAS Adoption Date (being 28 December 2018) after which no further 2019 Scheme Award Shares may be offered. During the six months ended 30 June 2026, no 2019 Scheme Award Shares were granted, cancelled, lapsed or vested. As at 30 June 2026, the remaining life of the 2019 Share Award Scheme is approximately two years and six months. During the six months ended 30 June 2026, as disclosed above, it is expected that the 2019 Share Award Scheme would be terminated upon the completion of the transfer of the shares held under the 2019 Share Award Scheme to the 2022 Share Award Scheme.

2022 SHARE AWARD SCHEME

On 3 March 2022, the Company adopted the 2022 Share Award Scheme, which was subsequently amended and restated pursuant to the resolutions of the Board on 23 May 2025 and 13 February 2026.

1. OBJECTIVE OF THE 2022 SHARE AWARD SCHEME

The objectives of the 2022 Share Award Scheme are (i) to recognise and motivate the contributions by certain eligible participants and to incentivise them and retain them for the continual operation and development of the Group; (ii) to attract suitable personnel for further development of the Group; and (iii) to provide certain eligible participants with a direct economic interest in attaining a long-term relationship between the Group and certain eligible participants.

2. PARTICIPANTS OF THE 2022 SHARE AWARD SCHEME AND THE BASIS OF DETERMINING THE ELIGIBILITY OF THE PARTICIPANTS

The Board may at its discretion grant shares of the Company pursuant to the 2022 Share Award Scheme ("2022 Scheme Award Shares") to (i) any employee and Director of the Company and/or any member of the Group and any related entity who, in the sole opinion of the Board, will contribute or have contributed to any member of the Group; and (ii) agents, consultants, suppliers or any other persons who provide services to any member of the Group and, in the sole opinion of the Board, will contribute or have contributed to any member of the Group (collectively the "2022 Scheme Selected Participants").

There is no service provider sublimit under the 2022 Share Award Scheme.

The 2022 Scheme Award Shares will be satisfied by existing shares of the Company and there are no shares that may be issued by the Company in respect of awards granted under the 2022 Share Award Scheme. Pursuant to the amendments to the Listing Rules on 1 January 2023, the Board amended the 2022 Share Award Scheme on 23 May 2025 to clarify and confirm that only grant of awards involving existing shares may be made thereunder and no grant of awards involving new shares may be made under the 2022 Share Award Scheme.

3. MAXIMUM NUMBER OF THE 2022 SCHEME AWARD SHARES

Pursuant to the Board resolutions dated 13 February 2026 and 31 March 2026, the Board approved, ratified and confirmed the adjustment of the 2019 Share Award Scheme and the 2022 Share Award Scheme by: (i) allocating the unused limit in the 2019 Share Award Scheme at the time (i.e. 121,009,120 shares) to the 2022 Share Award Scheme; (ii) transferring the outstanding 225,535,662 shares from the 2019 Share Award Scheme to become part of the trust asset under the 2022 Share Award Scheme subject to the terms and conditions thereunder and adjusting the limit of the 2022 Share Award Scheme accordingly; and (iii) terminating the 2019 Share Award Scheme. The aforesaid adjustment does not result in any increase in the aggregate limit of the 2019 Share Award Scheme and the 2022 Share Award Scheme taken as a whole (i.e. 896,632,160 shares). Upon completion of such adjustment, the limit of the 2022 Share Award Scheme would become 809,547,822 shares and the number of share awards that may be granted under the 2022 Share Award Scheme would be 707,451,822.

The number of 2022 Scheme Award Shares that may be granted under the scheme was 360,907,040 as at 1 January 2026 and 541,801,822 as at 30 June 2026. As at the date of this report, the number of 2022 Scheme Award Shares that may be granted under the scheme was 541,801,822, representing approximately 11.70% of the total number of issued shares of the Company.

There is no maximum entitlement to 2022 Scheme Award Shares stipulated for a 2022 Scheme Selected Participant under the 2022 Share Award Scheme.

4. AMOUNT PAYABLE FOR THE 2022 SCHEME AWARD SHARES

An offer of grant of 2022 Scheme Award Shares shall remain open for acceptance by the 2022 Scheme Selected Participants concerned for ten (10) business days from the date of the offer. In order to receive the 2022 Scheme Award Shares, the grantee shall submit to the Company the documents stipulated under the scheme and pay to the Company the amount specified in the award notice, thereafter the Company will instruct the trustee under the scheme in writing to transfer the corresponding 2022 Scheme Award Shares to the relevant grantee at nil consideration.

The purchase price of each 2022 Scheme Award Share (if any) shall be determined by the Board at the time of grant of the 2022 Scheme Award Shares under the 2022 Share Award Scheme.

Subject to the terms of the 2022 Share Award Scheme and subject to compliance with the Listing Rules, the Board may from time to time instruct the trustee of the 2022 Share Award Scheme in writing to directly or indirectly purchase shares of the Company in the market (on the exchange or off the exchange) or otherwise receive any shares of the Company of transfer from another trust under any other employee share award scheme of the Company to the trustee. Once purchased or received, the shares are to be held directly or indirectly by the trust for the benefit of the 2022 Scheme Selected Participant under the trust on and subject to the terms and conditions of the 2022 Share Award Scheme rules and trust deed.

5. VESTING PERIOD AND CONDITIONS

The Board may specify any vesting period of the 2022 Scheme Award Shares, or any conditions or performance targets that must be attained by the relevant 2022 Scheme Selected Participant before any 2022 Scheme Award Shares may be transferred to and vested in the 2022 Scheme Selected Participant.

6. REMAINING LIFE OF THE 2022 SHARE AWARD SCHEME

The 2022 Share Award Scheme shall be valid and effective for a term of ten (10) years commencing on 3 March 2022 after which no further 2022 Scheme Award Share may be offered. As at 30 June 2026, the remaining life of the 2022 Share Award Scheme is approximately five years and eight months.

The table below sets out the movements of the 2022 Scheme Award Shares during the period from 1 January 2026 to 30 June 2026:

Name	Date of grant	Vesting schedule	Grant price	Granted on the date of grant	Outstanding as at 1 January 2026	Vested during the six months ended 30 June 2026	Lapsed/ cancelled during the six months ended 30 June 2026	Outstanding as at 30 June 2026
Directors								
Mr. LIU Jianxiong (Note 3) (resigned from the directorship on 22 May 2026)	7 May 2026	1/3 of awards in 2026, 2027 and 2028, respectively	–	50,000,000	–	(16,666,666)	–	33,333,334
Sub-total				50,000,000	–	(16,666,666)	–	33,333,334
Ms. WU Liping (Note 2)	20 June 2025	20 June 2025	–	21,430,000	–	–	–	–
Ms. WU Liping (Note 3)	7 May 2026	1/3 of awards in 2026, 2027 and 2028, respectively	–	22,000,000	–	(7,333,333)	–	14,666,667
Sub-total				43,430,000	–	(7,333,333)	–	14,666,667
Mr. FANG Yu (Note 2)	20 June 2025	20 June 2025	–	36,800,000	–	–	–	–
Mr. FANG Yu (Note 3)	7 May 2026	1/3 of awards in 2026, 2027 and 2028, respectively	–	16,000,000	–	(5,333,333)	–	10,666,667
Sub-total				52,800,000	–	(5,333,333)	–	10,666,667
Ms. FENG Xiaoling (Note 2) (resigned from the directorship on 22 May 2026)	20 June 2025	20 June 2025	–	21,430,000	–	–	–	–
Ms. FENG Xiaoling (Note 3) (resigned from the directorship on 22 May 2026)	7 May 2026	1/3 of awards in 2026, 2027 and 2028, respectively	–	21,800,000	–	(7,266,666)	–	14,533,334
Sub-total				43,230,000	–	(7,266,666)	–	14,533,334
Other Grantees								
Employees (Note 1)	21 October 2022	5%, 10%, 15%, 20%, 25% and 25% upon completion of the Group's annual performance assessment of 2022, 2023, 2024, 2025, 2026 and 2027, respectively	–	20,750,000	12,705,000	(3,370,000)	(300,000)	9,035,000
Employees (Note 2)	20 June 2025	20 June 2025	–	1,686,000	–	–	–	–
Employees (Note 3)	7 May 2026	20% upon completion of the Group's annual performance assessment of 2025, 2026, 2027, 2028 and 2029, respectively	–	55,850,000	–	(11,696,665)	–	44,153,335
Sub-total				78,286,000	12,705,000	(15,066,665)	(300,000)	53,188,335
Total				267,746,000	12,705,000	(51,666,663)	(300,000)	126,388,337

Note 1: An aggregate of 20,750,000 2022 Scheme Award Shares were granted to 52 employees of the Group (who are neither a Director, chief executive officer or substantial shareholder of the Company nor their respective associates, nor are they the five highest paid individuals of the Company). The vesting of such shares is subject to the fulfilment of the conditions set out in the grant letter (including performance targets stipulated thereunder).

Such 2022 Scheme Award Shares shall be vested in the relevant participant in the following manner:

(a) 5% of the 2022 Scheme Award Shares shall be vested in the participant upon completion of the Group's annual performance assessment for the calendar year ending 31 December 2022;

(b) 10% of the 2022 Scheme Award Shares shall be vested in the participant upon completion of the Group's annual performance assessment for the calendar year ending 31 December 2023;

(c) 15% of the 2022 Scheme Award Shares shall be vested in the participant upon completion of the Group's annual performance assessment for the calendar year ending 31 December 2024;

(d) 20% of the 2022 Scheme Award Shares shall be vested in the participant upon completion of the Group's annual performance assessment for the calendar year ending 31 December 2025;

(e) 25% of the 2022 Scheme Award Shares shall be vested in the participant upon completion of the Group's annual performance assessment for the calendar year ending 31 December 2026; and

(f) the remaining 25% of the 2022 Scheme Award Shares shall be vested in the participant upon completion of the Group's annual performance assessment for the calendar year ending 31 December 2027.

The grantees are not required to pay any purchase price upon vesting of the awarded share. The closing price of the shares on the Stock Exchange immediately before the grant was HKD2.75 per share. The fair value of these 2022 Scheme Award Shares granted is based on the closing price of the shares on the grant date, which was HKD2.87 per share. During the six months ended 30 June 2026, 3,370,000 2022 Scheme Award Shares were vested and the weighted average closing price of the shares on the Stock Exchange immediately before the vesting date was approximately HKD1.83 per share.

Note 2: An aggregate of 1,686,000 2022 Scheme Award Shares were granted to 59 employees of the Group (who are neither a Director, chief executive officer or substantial shareholder of the Company nor their respective associates, nor are they the five highest paid individuals of the Company) and 79,660,000 2022 Scheme Award Shares were granted to three directors of the Company on 20 June 2025. The grantees are not required to pay any purchase price upon vesting of the awarded shares. The closing price of the shares on the Stock Exchange immediately before the grant was HKD1.85 per share. The fair value of these 2022 Scheme Award Shares granted is based on the closing price of the shares on the grant date, which was HKD2.04 per share.

Note 3: An aggregate of 55,850,000 2022 Scheme Award Shares were granted to 111 employees of the Group (who are neither a Director, chief executive officer or substantial shareholder of the Company nor their respective associates, nor are they the five highest paid individuals of the Company) and 109,800,000 2022 Scheme Award Shares were granted to four directors of the Company on 7 May 2026. The grantees are not required to pay any purchase price upon vesting of the awarded shares. The closing price of the shares on the Stock Exchange immediately before the grant was HKD2.01 per share. The fair value of these 2022 Scheme Award Shares granted is based on the closing price of the shares on the grant date, which was HKD2.03 per share. During the six months ended 30 June 2026, 48,296,663 2022 Scheme Award Shares were vested in May 2026, and the weighted average closing price of the shares on the Stock Exchange immediately before the vesting date was approximately HKD2.08 per share.

As at 30 June 2026, the ratio of the number of shares that may be issued in respect of options and awards granted under all share schemes adopted by the Company (i.e. 140,580,250) to the weighted average number of issued shares as at 30 June 2026 (i.e. 4,631,712,400) was approximately 3.04%.

For the purpose of Rule 17.06A of the Listing Rules for share schemes involving issue of new shares of the Company, during the six months ended 30 June 2026, (i) there was no participant with share options or awards granted or to be granted by the Company in excess of the 1% individual limit (as defined under Chapter 17 of the Listing Rules); (ii) there was no service provider with share options or awards granted or to be granted by the Company exceeding 0.1% of the total issued shares of the Company in any 12-month period; and (iii) the Company has not granted any share options or awards to any related entity participants or service providers.

INTERIM DIVIDEND

The Directors did not recommend the payment of any interim dividend for the six months ended 30 June 2026 (corresponding period of 2025: nil).

DIRECTOR'S RIGHTS TO ACQUIRE SHARES OR DEBENTURES

Apart from the details as disclosed under the section headed "DIRECTORS' AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY OR ITS ASSOCIATED CORPORATIONS" above, at no time during the six months ended 30 June 2026 were rights to acquire benefits by means of the acquisition of shares in or debentures of the Company granted to any Director or their respective spouse or children under 18 years of age, or were any such rights exercised by them; or was the Company and any of its subsidiaries a party to any arrangement to enable the Directors, or their respective spouse or children under 18 years of age, to acquire such rights in any other body corporate.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

During the six months ended 30 June 2026, there were no purchase, sales or redemptions of the Company's listed securities by the Company or any of its subsidiaries.

SUFFICIENCY OF THE PUBLIC FLOAT

Based on the information publicly available to the Company and to the best knowledge, information and belief of the Directors, the Directors confirm that the Company had maintained a sufficient public float as required under the Listing Rules throughout the six months ended 30 June 2026.

DISCLOSURE OF INFORMATION

The interim report of the Group for the six months ended 30 June 2026 containing all the relevant information required by the Listing Rules has been published on the websites of The Stock Exchange of Hong Kong Limited (http://www.hkexnews.hk) and the Company (http://www.lifetechmed.com).

On behalf of the Board
XIE Yuehui
Executive Director, Chairman and Chief Executive Officer

Hong Kong, 28 August 2026

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the six months ended 30 June 2026

The Board is pleased to announce the unaudited condensed consolidated results of the Group for the six months ended 30 June 2026 together with the comparative figures for the corresponding period of 2025 and the relevant explanatory notes as set out below.

		Six months ended 30 June	
	NOTES	**2026 RMB'000 (Unaudited)**	2025 RMB'000 (Unaudited)
Revenue	4	**600,830**	676,707
Cost of sales		**(134,934)**	(178,952)
Gross profit		**465,896**	497,755
Other income, expenses, gains and losses	5	**(19,679)**	50,365
Selling and distribution expenses		**(178,080)**	(250,905)
Administration expenses		**(147,230)**	(118,369)
Research and development expenses		**(132,163)**	(114,459)
Operating (loss) profit		**(11,256)**	64,387
Finance income, net		**2,499**	10,122
Share of (losses) gains of associates		**(3,021)**	5,291
(Loss) profit before tax	6	**(11,778)**	79,800
Income tax expense	7	**(36,505)**	(38,035)
(Loss) profit for the period		**(48,283)**	41,765
Other comprehensive (expense) income:			
Items that will not be reclassified to profit or loss:			
Fair value (loss) gain and exchange differences on investments in equity instruments at FVTOCI, net of tax		**(9,834)**	26,311
Items that may be reclassified subsequently to profit or loss:			
Exchange differences arising on translation of foreign operations		**1,901**	(614)
Other comprehensive (expense) income for the period		**(7,933)**	25,697
Total comprehensive (expense) income for the period		**(56,216)**	67,462
(Loss) profit for the period attributable to:			
Owners of the Company		**(34,348)**	55,074
Non-controlling interests		**(13,935)**	(13,309)
		(48,283)	41,765
Total comprehensive (expense) income attributable to:			
Owners of the Company		**(42,281)**	80,771
Non-controlling interests		**(13,935)**	(13,309)
		(56,216)	67,462
(Loss) earnings per share	9		
– Basic (RMB cents)		**(0.8)**	1.3
– Diluted (RMB cents)		**(0.8)**	1.3

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 30 June 2026

	NOTES	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Non-current assets			
Property, plant and equipment	10	907,523	921,096
Right-of-use assets	11	47,625	47,410
Investment properties		288,383	290,578
Intangible assets	10	800,488	779,184
Interests in associates	12	97,580	106,340
Financial assets at FVTPL	13	352,995	353,797
Equity instruments at FVTOCI	14	35,557	45,391
Deposits for acquisition of property, plant and equipment		15,672	17,922
Deferred tax assets		133,242	125,576
		2,679,065	2,687,294
Current assets			
Inventories		421,972	444,903
Trade receivables	15	122,028	161,797
Other receivables and prepayments	16	287,609	515,380
Financial assets at FVTPL	13	143,000	401,000
Fixed bank deposits		139,314	29,783
Restricted bank deposits		2,615	52,956
Cash and cash equivalents		953,772	719,315
		2,070,310	2,325,134
Current liabilities			
Trade and other payables	17	788,935	841,070
Contract liabilities		9,452	31,247
Tax liabilities		37,387	26,551
Lease liabilities		4,072	3,761
Financial liabilities at FVTPL	19	—	576,779
Bank borrowing	20	5,000	—
		844,846	1,479,408
Net current assets		1,225,464	845,726
Total assets less current liabilities		3,904,529	3,533,020

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 30 June 2026

	NOTES	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Non-current liabilities			
Government grants	18	**54,172**	53,636
Lease liabilities		**5,026**	4,276
Financial liabilities at FVTPL	19	**576,779**	—
		635,977	57,912
Net assets		**3,268,552**	3,475,108
Capital and reserves			
Share capital	21	**37**	37
Reserves		**3,319,352**	3,512,610
Equity attributable to owners of the Company		**3,319,389**	3,512,647
Non-controlling interests		**(50,837)**	(37,539)
Total equity		**3,268,552**	3,475,108

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the six months ended 30 June 2026

	Share capital RMB'000	Share premium RMB'000	Other reserve RMB'000	Translation reserve RMB'000	Statutory surplus reserve RMB'000 (Note i)	Investment valuation reserve RMB'000	Capital reserve RMB'000	Contribution reserve RMB'000 (Note ii)	Share option reserve RMB'000	Reserve for share award schemes RMB'000	Accumulated profits RMB'000	Total RMB'000	Non-controlling interests RMB'000	Total equity RMB'000
At 1 January 2025 (audited)	37	1,632,481	3,646	1,724	50,207	(126,848)	(3)	32,531	458,219	(432,118)	1,874,631	3,494,507	(19,078)	3,475,429
Profit (loss) for the period	–	–	–	–	–	–	–	–	–	–	55,074	55,074	(13,309)	41,765
Other comprehensive (expense) income for the period	–	–	–	(614)	–	26,311	–	–	–	–	–	25,697	–	25,697
Total comprehensive (expense) income for the period	–	–	–	(614)	–	26,311	–	–	–	–	55,074	80,771	(13,309)	67,462
Acquisition of a non-wholly control subsidiary	–	–	–	–	–	–	–	–	–	–	–	–	(3,323)	(3,323)
Recognition of equity-settled share-based payments	–	–	–	–	–	–	–	–	49,495	148,198	–	197,693	2,461	200,154
Exercise of share options	–	2,316	–	–	–	–	–	–	(830)	–	–	1,486	–	1,486
Exercise of scheme awarded shares	–	(1,849)	–	–	–	–	–	–	(5,948)	7,797	–	–	–	–
Transfer of purchased ordinary shares	–	–	–	–	–	–	–	–	–	(4,393)	–	(4,393)	–	(4,393)
Share of reserve of an associate	–	–	135	–	–	–	–	–	–	–	–	135	–	135
At 30 June 2025 (unaudited)	37	1,632,948	3,781	1,110	50,207	(100,537)	(3)	32,531	500,936	(280,516)	1,929,705	3,770,199	(33,249)	3,736,950
At 1 January 2026 (audited)	**37**	**1,543,573**	**3,845**	**3,089**	**50,207**	**(98,556)**	**(3)**	**32,531**	**684,705**	**(729,239)**	**2,022,458**	**3,512,647**	**(37,539)**	**3,475,108**
Loss for the period	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**(34,348)**	**(34,348)**	**(13,935)**	**(48,283)**
Other comprehensive income (expense) for the period	**–**	**–**	**–**	**1,901**	**–**	**(9,834)**	**–**	**–**	**–**	**–**	**–**	**(7,933)**	**–**	**(7,933)**
Total comprehensive income (expense) for the period	**–**	**–**	**–**	**1,901**	**–**	**(9,834)**	**–**	**–**	**–**	**–**	**(34,348)**	**(42,281)**	**(13,935)**	**(56,216)**
Capital contribution by non-controlling interest of subsidiaries	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**637**	**637**
Recognition of equity-settled share-based payments	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**17,124**	**107,894**	**–**	**125,018**	**–**	**125,018**
Exercise of scheme awarded shares	**–**	**(109,220)**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**109,220**	**–**	**–**	**–**	**–**
Transfer of purchased ordinary shares	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**6,518**	**–**	**6,518**	**–**	**6,518**
Transfer to reserve from offset of other receivables from Directors	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**(282,537)**	**–**	**(282,537)**	**–**	**(282,537)**
Share of reserve of an associate	**–**	**–**	**24**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**24**	**–**	**24**
At 30 June 2026 (unaudited)	**37**	**1,434,353**	**3,869**	**4,990**	**50,207**	**(108,390)**	**(3)**	**32,531**	**701,829**	**(788,144)**	**1,988,110**	**3,319,389**	**(50,837)**	**3,268,552**

Notes:

(i) Statutory surplus reserve is non-distributable and the transfer to this reserve is determined according to the relevant laws in the PRC and by the board of directors of the PRC subsidiaries in accordance with the article of association of the subsidiaries. Statutory surplus reserve can be used to make up for previous years' losses or convert into additional capital of the PRC subsidiaries of the Company.

(ii) Contribution reserve represents the difference between the fair value of the consideration paid for the acquisition of Lifetech Shenzhen from shareholders and the carrying amount of the share of net assets acquired in August 2006 and it is regarded as a deemed contribution from shareholders under merger accounting.

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

For the six months ended 30 June 2026

	Six months ended 30 June	
	2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
OPERATING ACTIVITIES		
Cash generated from operations	388,705	409,000
Income taxes paid	(33,335)	(17,727)
NET CASH FROM OPERATING ACTIVITIES	355,370	391,273
INVESTING ACTIVITIES		
Purchase of property, plant and equipment	(17,915)	(21,762)
Payments for intangible assets	(140)	(44)
Expenditure incurred and capitalised as intangible assets	(32,905)	(34,894)
Government grants received for acquisition of plant and equipment	450	—
Interest received from bank deposits	2,689	10,257
Proceeds from disposal of financial assets at FVTPL	401,000	311,000
Purchase of financial assets at FVTPL	(143,000)	(541,000)
Placement of fixed bank deposits	(138,433)	(100,432)
Decrease in restricted bank deposits	50,341	4,975
Release of fixed bank deposits	28,902	134,198
Acquisition of a non-wholly control subsidiary	—	(3,323)
Capital contribution to an associate	—	(32,000)
Refund from an associate	5,763	—
NET CASH USED IN INVESTING ACTIVITIES	156,752	(273,025)
FINANCING ACTIVITIES		
Bank borrowing raised	5,000	—
Interest paid for bank borrowing	(38)	—
Reserve for share award scheme from offset of other receivables from Directors	(282,537)	—
Proceeds from issue of shares upon exercise of share options	—	1,486
Repayments of lease liabilities	(2,476)	(2,131)
Repayments of Interest on lease liabilities	(152)	(135)
Capital contributed by non-controlling interest of subsidiaries	637	—
NET CASH USED IN FINANCING ACTIVITIES	(279,566)	(780)
NET INCREASE IN CASH AND CASH EQUIVALENTS	232,556	117,468
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD	719,315	665,755
EFFECT OF FOREIGN EXCHANGE RATE CHANGES	1,901	(614)
CASH AND CASH EQUIVALENTS AT END OF THE PERIOD, representing bank balances and cash	953,772	782,609

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 June 2026

1. GENERAL INFORMATION

The Company was incorporated in the Cayman Islands on 17 August 2006 as an exempted company with limited liability and its shares are listed on the Main Board of the Stock Exchange. Mr. XIE Yuehui, is the Chairman and Chief Executive Officer of the Company. The address of the registered office is PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands and the address of the principal place of business is LifeTech Scientific Building, No.22, Keji 12th Road South, High-tech Industrial Park, Nanshan District, Shenzhen, Guangdong Province, the PRC.

The Company is an investment holding company. The principal activities of the Group are developing, manufacturing and trading of advanced interventional medical devices for cardiovascular and peripheral vascular diseases and disorders.

The condensed consolidated financial statements are presented in Renminbi, which is the functional currency of the Company and the Group's major operating subsidiaries.

2. BASIS OF PREPARATION

The unaudited condensed consolidated financial statements of the Group for the six months ended 30 June 2026 have been prepared in accordance with International Accounting Standard 34 "Interim Financial Reporting" issued by the International Accounting Standards Board ("IASB") as well as with the applicable disclosure requirements of Appendix D2 to the Listing Rules.

3. PRINCIPAL ACCOUNTING POLICIES

The condensed consolidated financial statements have been prepared on the historical cost basis except for certain financial instruments, which are measured at fair value.

The accounting policies and methods of computation used in the condensed consolidated financial statements for the six months ended 30 June 2026 are consistent with those followed in the preparation of the Group's annual financial statements for the year ended 31 December 2025.

In addition, in the current interim period, the Group has applied a new interpretation and certain amendments to International Financial Reporting Standards ("IFRSs") issued by the IASB that are mandatorily effective for the current interim period. The application of the above new interpretation and amendments to IFRSs in the current interim period has had no material effect on the amounts reported in these condensed consolidated financial statements and/or disclosures set out in these condensed consolidated financial statements.

4. SEGMENT INFORMATION

The segment information reported internally was analysed on the basis of their products supplied by the Group's operating divisions which is consistent with the internal information that is regularly reviewed by executive Directors of the Company, the chief operating decision makers, for the purposes of resource allocation and assessment of performance.

4. SEGMENT INFORMATION - *CONTINUED*

The Group's operating segments under IFRSs 8 are as follows:

- Structural heart diseases business: trade, manufacture, research and development of devices related to structural heart diseases.
- Peripheral vascular diseases business: trade, manufacture, research and development of devices related to peripheral vascular diseases.
- Cardiac pacing and electrophysiology business: trade, manufacture, research and development of devices related to cardiac pacing and electrophysiology.

Information regarding the above segments is reported below.

(A) SEGMENT REVENUE AND RESULTS

The following is an analysis of the Group's revenue and results by operating and reportable segments:

For the six months ended 30 June 2026

	Structural heart diseases business RMB'000 (Unaudited)	Peripheral vascular diseases business RMB'000 (Unaudited)	Cardiac pacing and electrophysiology business RMB'000 (Unaudited)	Total RMB'000 (Unaudited)
SEGMENT REVENUE				
External sales	200,082	400,748	—	600,830
Segment profit	178,882	287,014	—	465,896
Unallocated income				
– Other income and other gains				26,303
– Finance income				2,689
Unallocated expense				
– Selling and distribution expenses				(178,080)
– Administration expenses				(147,230)
– Research and development expenses				(132,163)
– Other expenses and losses				(45,982)
– Finance costs				(190)
– Share of losses of associates				(3,021)
Losses before tax				(11,778)

4. SEGMENT INFORMATION - *CONTINUED*

(A) SEGMENT REVENUE AND RESULTS - *CONTINUED*

For the six months ended 30 June 2025

	Structural heart diseases business RMB'000 (Unaudited)	Peripheral vascular diseases business RMB'000 (Unaudited)	Cardiac pacing and electrophysiology business RMB'000 (Unaudited)	Total RMB'000 (Unaudited)
SEGMENT REVENUE				
External sales	271,539	391,693	13,475	676,707
Segment profit	237,686	258,214	1,855	497,755
Unallocated income				
– Other income and other gains				63,730
– Finance income				10,257
– Share of gains of associates				5,291
Unallocated expense				
– Selling and distribution expenses				(250,905)
– Administration expenses				(118,369)
– Research and development expenses				(114,459)
– Other expenses and losses				(13,365)
– Finance costs				(135)
Profit before tax				79,800

Segment profit represents the gross profit earned by each segment without allocation of all other items of income and expenses, as set out above. This is the measure reported to the chief operating decision makers, the executive Directors of the Company, for the purposes of resources allocation and assessment of segment performance.

4. SEGMENT INFORMATION - *CONTINUED*

(B) SEGMENT ASSETS AND LIABILITIES

The following is an analysis of the Group's assets and liabilities by operating and reportable segments:

SEGMENT ASSETS

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Operating segments:		
Structural heart diseases business	**586,213**	618,308
Peripheral vascular diseases business	**1,174,187**	1,020,646
Cardiac pacing and electrophysiology business	**45,632**	70,595
Total segment assets	**1,806,032**	1,709,549
Unallocated assets		
Interests in associates	**97,580**	106,340
Property, plant and equipment	**402,158**	553,963
Right-of-use assets	**47,625**	47,410
Investment properties	**288,383**	290,578
Deferred tax assets	**133,242**	125,576
Financial assets at FVTPL	**495,995**	754,797
Equity instruments at FVTOCI	**35,557**	45,391
Other receivables and prepayments	**287,609**	515,380
Cash and cash equivalents	**953,772**	719,315
Restricted bank deposits	**2,615**	52,956
Fixed bank deposits	**139,314**	29,783
Intangible assets	**43,821**	43,468
Deposits for acquisition of property, plant and equipment	**15,672**	17,922
Consolidated assets	**4,749,375**	5,012,428

4. SEGMENT INFORMATION - *CONTINUED*

(B) SEGMENT ASSETS AND LIABILITIES - *CONTINUED*

SEGMENT LIABILITIES

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Operating segments:		
Structural heart diseases business	**111,570**	137,302
Peripheral vascular diseases business	**223,476**	226,646
Cardiac pacing and electrophysiology business	**27,099**	22,733
Total segment liabilities	**362,145**	386,681
Unallocated liabilities		
Other payables	**434,858**	482,312
Lease liabilities	**9,098**	8,037
Bank borrowing	**5,000**	—
Tax liabilities	**37,387**	26,551
Government grants	**55,556**	56,960
Financial liabilities at FVTPL	**576,779**	576,779
Consolidated liabilities	**1,480,823**	1,537,320

For the purposes of monitoring segment performances and allocating resources between segments:

- All assets are allocated to operating segments other than interests in associates, certain property, plant and equipment, right-of-use assets, investment properties, deferred tax assets, financial assets at FVTPL, equity instruments at FVTOCI, other receivables and prepayments, cash and cash equivalents, fixed bank deposits, restricted bank deposits, certain intangible assets and deposits for acquisition of property, plant and equipment; and

- All liabilities are allocated to operating segments in arriving at segment liabilities, which exclude certain other payables, bank borrowing, tax liabilities, government grants (including current portion under other payables and non-current portion), lease liabilities and financial liabilities at FVTPL.

5. OTHER INCOME, EXPENSES, GAINS AND LOSSES

	Six months ended 30 June	
	2026	2025
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Other income and expenses		
Government grants (note 18)	**3,642**	7,989
Rental income generated from investment properties	**17,112**	17,712
Depreciation of investment properties	**(4,944)**	(4,722)
Others	**(1,844)**	(4,246)
	13,966	16,733
Other gains and losses		
Losses on disposal of property, plant and equipment and intangible assets	**(33)**	(269)
Gains from changes in fair value of hybrid funds	**1,783**	13,996
Gains (losses) from changes in fair value of equity funds	**3,766**	(3,260)
Unrealised foreign exchange losses in financial assets at FVTPL	**(6,351)**	(868)
Other net foreign exchange (losses) gains	**(32,810)**	24,033
	(33,645)	33,632
	(19,679)	50,365

6. (LOSS) PROFIT BEFORE TAX

	Six months ended 30 June	
	2026 **RMB'000** **(Unaudited)**	2025 RMB'000 (Unaudited)
(Loss) profit before tax has been arrived at after charging (crediting):		
Staff costs, including Directors' remuneration		
Directors' fees	**315**	360
Salaries, wages, performance related bonus and other benefits	**196,202**	168,296
Share-based payment expenses	**123,058**	193,500
Retirement benefits scheme contributions	**18,902**	18,658
Less: capitalised in development costs, construction in progress and inventories	**(20,949)**	(21,238)
	317,528	359,576
Cost of inventories recognised as expenses	**134,934**	178,952
Depreciation of property, plant and equipment	**30,714**	26,415
Depreciation of right-of-use assets	**3,361**	2,678
Depreciation of investment properties	**4,944**	4,722
Amortisation of intangible assets	**13,701**	8,935
Total depreciation and amortisation	**52,720**	42,750
Gross rental income from investment properties	**(17,112)**	(17,712)
Less: direct operating expenses incurred for investment properties that generated rental income during the period	**4,944**	4,722
	(12,168)	(12,990)

7. INCOME TAX EXPENSE

	Six months ended 30 June	
	2026 **RMB'000** **(Unaudited)**	2025 RMB'000 (Unaudited)
Current tax charge:		
PRC Enterprise Income Tax ("PRC EIT")	**26,003**	30,415
Hong Kong Profits Tax	**18,168**	8,530
Deferred tax credit:		
Current period	**(7,666)**	(910)
	36,505	38,035

The Company is tax exempted under the laws of the Cayman Islands.

Lifetech Scientific International Holding Limited, a subsidiary of the Company, is subject to Hong Kong Profits Tax. On 21 March 2018, the Hong Kong Legislative Council passed The Inland Revenue (Amendment) (No. 7) Bill 2018 (the "Bill") which introduced the two-tiered profits tax rates regime. The Bill was signed into law on 28 March 2018 and was gazetted on the following day. Under the two-tiered profits tax rates regime, the first HKD2.0 million of profits of the qualifying group entity will be taxed at 8.25%, and profits above HKD2.0 million will be taxed at 16.5%. The profits of group entities not qualifying for the two-tiered profits tax rates regime will continue to be taxed at a flat rate of 16.5% on assessable profits earned in Hong Kong.

Under the Law of the PRC on Enterprise Income Tax (the "EIT Law") and Implementation Regulation of the EIT Law, the tax rate of the PRC subsidiaries is 25% except for Lifetech Shenzhen, the major operating subsidiary in the PRC. Lifetech Shenzhen has been qualified as a High and New Technology Enterprise since 2009, which was subsequently renewed in November 2023, and therefore Lifetech Shenzhen is entitled to a preferential corporate income tax rate of 15% for each of the six months ended 30 June 2025 and 30 June 2026. Biotyx Medical was qualified as High and New Technology Enterprise since 2021, which was subsequently renewed in December 2025, and therefore Biotyx Medical is entitled to a preferential income tax rate of 15% for the six months ended 30 June 2026. The qualification of High and New Technology Enterprises is subject to review by relevant authorities in the PRC for every three years.

The applicable income tax rate of Lifetech Scientific India Private Ltd. in the jurisdiction of India is 30.9% on its taxable profits. No provision for taxation in India has been made as there is no assessable profits in India for both periods.

Taxation arising in other jurisdictions is calculated at the rates prevailing in the relevant jurisdictions.

8. DIVIDENDS

No dividend was paid, declared or proposed during the interim periods ended 30 June 2026 and 2025, nor has any dividend been proposed since the end of the Reporting Period.

9. (LOSS)EARNINGS PER SHARE

The calculation of basic and diluted loss/earnings per share attributable to the owners of the Company is based on the following data:

	Six months ended 30 June	
	2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
(Loss) earnings:		
(Loss) earnings for the purposes of basic and diluted loss/earnings per share	**(34,348)**	55,074

	Six months ended 30 June	
	2026 '000 (Unaudited)	2025 '000 (Unaudited)
Number of shares:		
Weighted average number of ordinary shares for the purpose of basic loss/earnings per share (Note)	**4,383,710**	4,344,028
Effect of dilutive potential ordinary shares:		
Share options	**—**	130
Award shares	**19,712**	6,490
Weighted average number of ordinary shares for the purpose of diluted loss/earnings per share (Note)	**4,403,422**	4,350,648

The computation of diluted loss/earnings per share does not assume the conversion of certain of the Company's share options because the exercise price of those options was higher than the average market prices for shares for the six months ended 30 June 2026 and 2025.

Note: Treasury shares are deducted from total number of shares in issue for the purpose of calculating loss/earnings per share.

10. PROPERTY, PLANT AND EQUIPMENT AND INTANGIBLE ASSETS

During the six months ended 30 June 2026, the Group spent approximately RMB16,738,000 (corresponding period of 2025: approximately RMB21,334,000) for the acquisition of equipment and improvement of plant to enhance its manufacturing capabilities. In addition, the Group also incurred approximately RMB475,000 (corresponding period of 2025: approximately RMB10,533,000) for construction cost of the industrial park.

During the six months ended 30 June 2026, the Group incurred approximately RMB 34,865,000 (corresponding period of 2025: approximately RMB41,548,000) of R&D expenditure for new products, and incurred approximately RMB140,000 (corresponding period of 2025: approximately RMB44,000) for the purchase of other intangible assets.

11. RIGHT-OF-USE ASSETS

	Leasehold lands RMB'000	Leased properties RMB'000	Total RMB'000
As at 1 January 2026			
Carrying amount (audited)	39,297	8,113	47,410
For the six months ended 30 June 2026			
Additions	—	3,576	3,576
Depreciation charge	(642)	(2,719)	(3,361)
As at 30 June 2026			
Carrying amount (unaudited)	38,655	8,970	47,625

During the six months ended 30 June 2026, the Group leases various offices, warehouses and staff dormitories. Lease contracts are entered into for fixed term of 1 month to 4 years. Lease terms are negotiated on individual basis and contain different terms. In determining the lease term and assessing the length of the non-cancellable period, the Group applies the definition of a contract and determines the period for which the contract is enforceable.

During the six months ended 30 June 2026, the short-term lease expenses amounted to approximately RMB767,000.

In addition, lease liabilities of approximately RMB9,098,000 (31 December 2025: approximately RMB8,037,000) are recognised with related right-of-use assets of approximately RMB8,970,000 (31 December 2025: approximately RMB8,113,000) as at 30 June 2026. The lease agreements do not impose any covenants other than the security interests in the leased properties that are held by the lessor and the relevant leased properties may not be used as security for borrowing purposes. As at 30 June 2026, the Group has no lease commitments as leasee.

12. INTERESTS IN ASSOCIATES

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Cost of investment in associates	102,485	108,224
Share of post-acquisition losses and other comprehensive expenses	(4,905)	(1,884)
	97,580	106,340

12. INTERESTS IN ASSOCIATES - *CONTINUED*

The following sets out the particulars of the associates of the Group as at 30 June 2026 and 31 December 2025, which in the opinion of the Directors, principally affected the results or net assets of the Group:

Name of entities	Country of incorporation	Place of business	Proportion of ownership interest held by the Group		Principal activities
			30 June 2026	31 December 2025	
深圳市先健創興天使投資合夥企業(有限合夥) (Note i)	The PRC	The PRC	**40.00%**	40.00%	Investing
Shenzhen High-Performance Medical Device National Research Institute Co., Ltd. (深圳高性能醫療器械國家研究院有限公司) ("Joint Laboratory") (Note ii)	The PRC	The PRC	**10.42%**	10.42%	Developing medical devices
Shenzhen Lifetech Cardio Medical Electronics Co., Ltd. (深圳市先健心康醫療電子有限公司) ("Shenzhen Cardio") (Note ii)	The PRC	The PRC	**13.10%**	13.10%	Developing, manufacturing and trading of medical devices
Shenzhen Advanced Medical Services Co., Ltd. (深圳市領先醫療服務有限公司) ("Advanced Medical") (Note iii)	The PRC	The PRC	**40.00%**	40.00%	Consulting and technology services

Notes:

(i) The Group is able to exercise significant influence over the partnership enterprise because the Group is entitled to appoint three of the seven members under its Investment Committee.

(ii) The Group continues to be able to exercise significant influence over Joint Laboratory and Shenzhen Cardio because the Group is entitled to appoint one of the five directors under its Articles of Association.

(iii) The Group is able to exercise the significant influence over Advanced Medical.

All of these associates are accounted for using the equity method in these consolidated financial statements. The Group considers none of its associates is individually material.

Financial information of these companies has not been disclosed since these associates are immaterial to the Group.

13. FINANCIAL ASSETS AT FVTPL

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Financial assets mandatorily measured at FVTPL:		
Non-current assets		
Unlisted funds		
– Equity funds (Note i)	**202,290**	204,875
– Hybrid funds (Note ii)	**50,625**	48,842
Investment in an associate held via preference shares (Note iii)	**100,000**	100,000
Others	**80**	80
	352,995	353,797
Current assets		
Short-term bank structured deposits (Note iv)	**143,000**	401,000

Notes:

(i) On 25 May 2018, the Group entered into a subscription agreement with certain independent third parties pursuant to which the Group agreed to subscribe for interest of a private equity fund, as a limited partner, for an aggregate consideration of USD6,000,000 (equivalent to approximately RMB38,202,000) in cash. The 2018 Equity Fund principally invests in securities or assets of companies that are involved in the healthcare industry, with a particular focus on cross-border innovative late-stage venture opportunities and crossover investments.

On 24 October 2022, the Group entered into a subscription agreement with certain independent third parties pursuant to which the Group agreed to subscribe for interest of a private equity fund, as a limited partner, for an aggregate consideration of USD20,000,000 (equivalent to approximately RMB144,378,000) in cash. The purposes of the 2022 Equity Fund are to seek capital appreciation primarily by acquiring, holding and disposing of securities, independently or with others, primarily in non-listed or, sometimes, listed persons involved in the healthcare industry, with a particular focus on leading innovative technologies.

The Group holds approximately 9.69% (31 December 2025: approximately 9.69%) and approximately 4.60% (31 December 2025: approximately 4.60%) interest respectively in the 2018 Equity Fund and 2022 Equity Fund as at 30 June 2026.

(ii) On 8 January 2021, the Group entered into a contract to purchase a hybrid fund unit with a financial institution, which was accounted for as financial assets at FVTPL on initial recognition, for a consideration of RMB10,000,000 in cash.

On 28 November 2023, the Group entered into a contract to purchase a hybrid fund unit with a financial institution, which was accounted for as financial assets at FVTPL on initial recognition, for a consideration of RMB50,000,000 in cash.

13. FINANCIAL ASSETS AT FVTPL - *CONTINUED*

Notes: - *continued*

(iii) On 6 June 2025, the Group entered into a series of agreements through Lifetech Shenzhen, to make a cash investment in Affector Medtech, for a total consideration of RMB150,000,000. Upon completion of all stages of the investment, Lifetech Shenzhen will hold 30% equity interest in Affector Medtech.

As at 31 December 2025 and 30 June 2026, Lifetech Shenzhen has completed the first stage of capital injection, for a consideration of RMB100,000,000 in cash and holds a 22.22% equity interest in Affector Medtech.

The Group is able to exercise significant influence over Affector Medtech because the Group is entitled to appoint two of the seven directors under the articles of association of Affector Medtech. Pursuant to the above mentioned agreements, if Affector Medtech is unable to meet certain specified conditions under agreed milestone, Lifetech Shenzhen will have the right to exercise the liquidation preference and redemption rights. Taking into account the substantive redemption and liquidation preference features, the Directors of the Company consider these preferred shares do not carry rights that are substantially the same as the Affector Medtech's ordinary shares and accordingly these preferred shares are accounted for as financial instruments measured at FVTPL under IFRS 9.

In the opinion of the directors of the Company, the investment is held for long-term strategic investment purposes and as such, the investment is classified as non-current asset. In the opinion of the directors of the Company, the fair value change in relation to the investment during the six months ended 30 June 2026 is insignificant.

(iv) As at 30 June 2026, the Group had short-term bank structured deposits of RMB143.0 million (31 December 2025: RMB401.0 million).

The above equity funds are managed by fund/investment managers, and the Group does not have rights to engage in the management of the equity funds. The Group, as a limited partner in the equity funds does not have the rights to participate in the financial and operating policy decisions of the equity funds. As such, the Group does not have significant influence over the equity funds, and therefore they are not accounted for as associates.

The equity funds and hybrid funds are accounted for as financial assets at FVTPL in accordance with IFRS 9. In the opinion of the Directors of the Company, these funds are held for long-term strategic investment purposes and as such, the investments are classified as non-current assets.

14. EQUITY INSTRUMENTS AT FVTOCI

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Listed:		
– Equity securities listed in Hong Kong (Note)	**35,557**	45,391

Note:

On 21 September 2022, the Group entered into a subscription agreement with Jenscare Scientific pursuant to which the Group agreed to subscribe for shares of Jenscare Scientific upon the initial public offering, as a cornerstone investor, for an aggregate consideration of USD20,000,000 (equivalent to approximately RMB143,947,000) in cash with the subscription price of HKD27.8 per share. There is a lock-up period of six months upon the initial public offering on 10 October 2022.

In the opinion of the Directors of the Company, the investment is held for long-term strategic investment purposes and as such, it is classified as non-current asset.

15. TRADE RECEIVABLES

The Group normally allows a credit period of 30 to 180 days (corresponding period of 2025: 30 to 180 days) to its trade customers. The following is an ageing analysis of trade receivables, net of allowance for credit losses, presented based on the invoice dates at the end of the Reporting Period, which approximated the respective revenue recognition dates:

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
1 - 90 days	**98,340**	147,602
91 - 180 days	**16,055**	6,795
181 - 365 days	**3,643**	2,900
Over 365 days	**3,990**	4,500
	122,028	161,797

16. OTHER RECEIVABLES AND PREPAYMENTS

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Other debtors (Note i)	138,645	123,353
Value added tax deductible	48,647	46,306
Prepayments	58,166	31,645
Advance to employees - interest free	37,073	35,028
Amounts due from directors - others (Note ii)	—	274,869
Rental deposits	1,969	1,592
Other deposits	3,109	2,587
	287,609	515,380

Notes:

(i) These are unsecured and interest-free. In the opinion of the directors, the Group will demand for repayments within one year from the end of the Reporting Period and the amounts are therefore considered as current.

Included in the amount as at 30 June 2026 was the balance to an associate amounting to approximately RMB3,709,000 (31 December 2025: approximately RMB3,313,000).

In addition, the amount as at 31 December 2025 and 30 June 2026 also includes receivables from certain employees, who were appointed as directors of the Company subsequent to the relevant transactions (one of whom resigned from the directorship on 22 May 2026), amounting to approximately RMB66,143,000 (31 December 2025: approximately RMB66,143,000). Such receivables represent amounts advanced by the Company on their behalf and recoverable from them. These receivables are non-trade in nature, unsecured, interest-free and repayable on demand.

(ii) As at 31 December 2024, the amount represents deferred payment from employees of the Group who were granted 230,945,000 shares under the 2019 Share Award Scheme adopted on 28 December 2018 for the purchase price of HKD1.35 per share. The corresponding shares remained at the scheme pending payment. At the time of grant and acceptance of such share awards, none of these employees was a connected person of the Company as defined under the Listing Rules.

On 21 November 2025, these employees were appointed as directors of the Company. During the year ended 31 December 2025, an aggregate of consideration of approximately RMB6,596,000, representing the consideration of 5,409,338 ordinary shares, have been settled by these directors. As at 31 December 2025, the amount due from the directors represents the consideration receivable for the remaining 225,535,662 shares (the "Outstanding Shares").

Subsequently, on 30 March 2026, these directors had irrevocably surrendered and foregone the Outstanding Shares without any recourse against the Company, any of its subsidiaries or any of their respective directors, officers, employees, agents, advisers and other representatives. Accordingly, as at 30 June 2026, the Outstanding Shares were recognised as reserve for share award scheme and the corresponding amount due was offset. This is considered as non-cash transaction of the Company.

17. TRADE PAYABLES

The credit period granted by suppliers to the Group ranged from 30 to 120 days (corresponding period of 2025: 30 to 120 days). The following is an ageing analysis of trade payables presented based on the invoice dates at the end of the Reporting Period:

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
0 - 30 days	15,537	10,100
31 - 60 days	11,657	11,862
61 - 120 days	18,264	21,455
Over 120 days	41,839	41,286
	87,297	84,703

18. GOVERNMENT GRANTS

	Six months ended 30 June	
	2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Government grant related to assets:		
At the beginning of the period	56,960	54,451
Additions	450	—
Released to profit or loss	(1,854)	(6,073)
At the end of the period	55,556	48,378

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Classified as:		
Current liabilities (included in other payables)	1,384	3,324
Non-current liabilities	54,172	53,636
	55,556	56,960

18. GOVERNMENT GRANTS - *CONTINUED*

Government grants include subsidies in relation to the acquisition of plant, equipment and the research and development of medical devices. The amount is transferred to income on a systematic basis over the estimated useful lives of the related assets.

During the six months ended 30 June 2026, the Group recognised income of approximately RMB3,642,000 (corresponding period of 2025: approximately RMB7,989,000) of which approximately RMB1,788,000 (corresponding period of 2025: approximately RMB1,916,000) was received and directly recognised in profit or loss.

19. FINANCIAL LIABILITIES AT FVTPL

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Capital injection from other investors	**576,779**	576,779

During the year ended 31 December 2020, Lifetech Shenzhen, a wholly-owned subsidiary of the Company, entered into Series A Agreement with certain independent third parties for issuance of shares of Biotyx Medical with a total consideration of RMB135,000,000. Pursuant to the Series A Agreement, during the year ended 31 December 2020, Biotyx Medical received the first capital injection of RMB67,500,000. During the year ended 31 December 2021, Biotyx Medical received the second capital injection of RMB67,500,000. Upon the completion of the above transaction, the Group's equity interest in Biotyx Medical decreased from 66.17% to 57.44%.

During the year ended 31 December 2023, Lifetech Shenzhen entered into Series B Agreement with certain independent third parties for issuance of shares of Biotyx Medical, with a total consideration of RMB202,000,000. Pursuant to the Series B Agreement, during the year ended 31 December 2023, Biotyx Medical received the total capital injection of RMB202,000,000. Upon the completion of the above transaction, the Group's equity interest in Biotyx Medical decreased from 57.44% to 49.64%.

During the six months ended 30 June 2026, Lifetech Shenzhen entered into Series C Agreement with certain independent third parties for issuance of shares of Biotyx Medical, with a total consideration of RMB121,546,000. Pursuant to the Series C Agreement, the capital injection is payable upon the satisfaction of certain conditions. As at 30 June 2026, the capital injection had not yet been received. Upon the completion of the above transaction, the Group's equity interest in Biotyx Medical will decrease from 49.64% to 48.13%.

Pursuant to the above mentioned Series A, Series B and Series C Agreements, if Biotyx Medical is unable to meet certain specified conditions within the agreed timeframe, the holders of these shares will have the right to require Biotyx Medical to redeem all of their shares at the predetermined consideration. Accordingly, these shares are classified as a financial liability.

As at 30 June 2026, the above-mentioned agreed timeframe according to Series C Agreement was extended, and therefore the financial liabilities at FVTPL are reclassified as non-current liabilities.

20. BANK BORROWING

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Unsecured bank borrowing	5,000	—
The carrying amount of the above borrowing is repayable*:		
Within one year	5,000	—
Amount shown under current liabilities	5,000	—

* The amount due is based on scheduled repayment date set out in the loan agreement.

21. SHARE CAPITAL

	Number of Shares	Amount USD
Ordinary Shares		
Authorised:		
At 1 January 2025, 31 December 2025 and 30 June 2026 at USD0.00000125 each	40,000,000,000	50,000

	Number of Shares	Amount USD	Shown in the condensed consolidated financial statements as RMB'000
Issued and fully paid:			
At 1 January 2025	4,630,612,400	5,789	37
Exercise of share options	1,100,000	1	— *
At 31 December 2025	4,631,712,400	5,790	37
Exercise of share options	—	—	—
At 30 June 2026	**4,631,712,400**	**5,790**	**37**

* Less than RMB1,000.

22. SHARE-BASED PAYMENT TRANSACTIONS

(A) SHARE OPTION SCHEME

EQUITY-SETTLED SHARE OPTION SCHEME OF THE COMPANY:

The Previous Scheme adopted by the Company on 22 October 2011 which was amended by a unanimous written resolution of the Board on 5 May 2015 was terminated pursuant to an ordinary resolution passed by the shareholders at the EGM on 17 September 2021, and the shares already granted are still effective until the end of the exercisable period. A new Share Option Scheme in place of the Previous Scheme was adopted by the Company with effect from 17 September 2021 which has a term of 10 years.

The terms, conditions and fair values at the grant date of the grants are as follows:

	Number of options	Fair value HKD	Weighted average exercise price HKD	Weighted average fair value per share option HKD
Options granted to executives, Directors and employees on:				
on 31 March 2021	33,320,000	53,044,000	3.5700	1.5920
on 12 November 2021	101,800,000	188,423,000	3.5900	1.8509
on 10 December 2021	11,000,000	21,350,000	3.8360	1.9409
on 24 January 2024	174,750,000	172,908,000	1.9500	0.9895
	320,870,000	435,725,000		
Options granted to consultants on 10 December 2021 (Note)	24,000,000	46,581,000	3.8360	1.9409

Note: These consultants perform services that are similar to services currently provided by employees.

The above share options are vested in instalments over an explicit vesting period of 12 months to 5.5 years.

22. SHARE-BASED PAYMENT TRANSACTIONS - *CONTINUED*

(A) SHARE OPTION SCHEME - *CONTINUED*

EQUITY-SETTLED SHARE OPTION SCHEME OF THE COMPANY: - CONTINUED

The number and weighted average exercise prices of share options under the Previous Scheme and the Share Option Scheme are as follows:

	Six months ended 30 June			
	2026		2025	
	Weighted average exercise price HKD	**Number of options**	Weighted average exercise price HKD	Number of options
Outstanding at the beginning of the period	**2.7313**	**309,478,750**	2.5082	389,204,600
Granted during the period	**—**	**—**	—	—
Exercised during the period	**—**	**—**	1.4640	(1,100,000)
Lapsed during the period (Note)	**3.0208**	**(1,235,000)**	1.6043	(76,077,100)
Outstanding as at the end of the period	**2.7302**	**308,243,750**	2.7323	312,027,500
Exercisable as at the end of the period	**3.0491**	**140,580,250**	3.1980	93,650,500

Note: During the period, certain employees resigned or failed to pass the performance assessment and respective share options were lapsed accordingly.

All the share options granted are exercisable by the grantees upon vesting.

For the six months ended 30 June 2026, the Group recognised approximately RMB12,801,000 (corresponding period of 2025: approximately RMB33,377,000) share-based payment expenses in profit or loss in relation to the Previous Scheme and the Share Option Scheme. In addition, approximately RMB307,000 (corresponding period of 2025: approximately RMB1,329,000) was capitalised in development costs.

EQUITY-SETTLED SHARE OPTION SCHEME OF BIOTYX MEDICAL:

Biotyx Medical adopted a share option scheme (the "Biotyx Medical Scheme"), of which to enable Biotyx Medical to grant options to directors, supervisors, senior management, other management personnel, key employees and business partner, who have contributed or may contribute to the development and growth of Biotyx Medical and/or any entity in which Biotyx Medical holds an equity interest.

22. SHARE-BASED PAYMENT TRANSACTIONS - *CONTINUED*

(A) SHARE OPTION SCHEME - *CONTINUED*

EQUITY-SETTLED SHARE OPTION SCHEME OF BIOTYX MEDICAL: - CONTINUED

The following table discloses movements of the Biotyx Medical Scheme during the six months ended 30 June 2026 and 2025:

	Six months ended 30 June			
	2026		2025	
	Weighted average exercise price RMB	Number of options	Weighted average exercise price RMB	Number of options
Outstanding at the beginning of the period	**0.2547**	**10,484,200**	0.2547	11,485,500
Exercised during the period	**—**	**—**	—	—
Lapsed during the period	**—**	**—**	0.2547	(824,600)
Outstanding as at the end of the period	**0.2547**	**10,484,200**	0.2547	10,660,900
Exercisable as at the end of the period	**0.2547**	**10,484,200**	0.2547	10,660,900

Details of specific categories of share options under the Biotyx Medical Scheme are as follows:

Granted on 1 November 2023

Types	Vesting period	Exercisable period	Grant date fair value per option RMB
Batch I	N/A	1 November 2023 - 1 November 2028	22.4467
Batch II	N/A	1 November 2023 - 1 November 2028	22.4467
Batch III	3 months	31 January 2024 - 31 January 2029	22.4467
Batch IV	3 months	31 January 2024 - 31 January 2029	22.4467
Batch V	15 months	31 January 2025 - 31 January 2030	22.4467
Fair value of share options granted			RMB269,711,000

The fair value of shares granted was measured by reference to the price at which third party investors made contributions to Biotyx Medical in 2023.

22. SHARE-BASED PAYMENT TRANSACTIONS - *CONTINUED*

(A) SHARE OPTION SCHEME - *CONTINUED*

EQUITY-SETTLED SHARE OPTION SCHEME OF BIOTYX MEDICAL: - CONTINUED

For the six months ended 30 June 2025, the Group recognised approximately RMB335,000 share-based payment expenses in profit or loss in relation to the Biotyx Medical Scheme. In addition, approximately RMB4,551,000 was capitalised in development costs.

(B) SHARE AWARD SCHEME

EQUITY-SETTLED SHARE AWARD SCHEME OF THE COMPANY

The 2019 Share Award Scheme

On 28 December 2018, the Company adopted the 2019 Share Award Scheme which was subsequently amended by unanimous written resolutions of the Board on 29 April 2019.

The 2019 Share Award Scheme shall be valid and effective for a term of 10 years commencing on 28 December 2018, after which no further 2019 Scheme Award Shares may be offered.

As at 31 December 2023, the remaining shares have been issued to such grantees and there are no outstanding shares under the 2019 Share Award Scheme.

For the six months ended 30 June 2026 and 2025, the Group has not recognised any expenses in the profit or loss.

The 2022 Share Award Scheme

On 3 March 2022, the Company adopted the 2022 Share Award Scheme, which was subsequently amended and restated pursuant to the resolutions of the Board on 23 May 2025 and 13 February 2026.

The 2022 Share Award Scheme shall be valid and effective for a term of 10 years commencing on 3 March 2022, after which no further 2022 Scheme Award Shares may be offered.

During the year ended 31 December 2025, the Company instructed the Futu Trustee Limited to purchase an aggregate of 230,000,000 (2024: 101,780,000) ordinary shares at a consideration of approximately RMB397,132,000 (2024: approximately RMB146,637,000) in accordance with the 2022 Share Award Scheme.

On 21 October 2022, a total of 20,750,000 shares of the Company have been granted by the Company to certain senior management/employees at no cost and the vesting period ranges from six months to six years.

22. SHARE-BASED PAYMENT TRANSACTIONS - *CONTINUED*

(B) SHARE AWARD SCHEME - *CONTINUED*

EQUITY-SETTLED SHARE AWARD SCHEME OF THE COMPANY - CONTINUED

The 2022 Share Award Scheme - *continued*

On 20 June 2025, a total of 81,346,000 shares of the Company have been granted by the Company to certain senior management/employees at no cost and were vested on the same date of the grant.

On 7 May 2026, a total of 165,650,000 shares of the Company have been granted by the Company to certain senior management/employees at no cost and the vesting period ranges from zero to four years.

The following table discloses movements of the 2022 Share Award Scheme during the six months ended 30 June 2026 and 2025:

	Six months ended 30 June	
	2026 Number of shares	2025 Number of shares
Unvested at the beginning of the period	**12,705,000**	15,615,000
Granted during the period	**165,650,000**	81,346,000
Vested during the period	**(51,666,663)**	(83,618,500)
Lapsed during the period	**(300,000)**	(255,000)
Unvested as at the end of the period	**126,388,337**	13,087,500

The fair value of the granted shares was based on the closing price of the shares on the grant date.

For the six months ended 30 June 2026, the Group recognised approximately RMB106,477,000 (corresponding period of 2025: approximately RMB156,091,000) share-based payment expenses in profit or loss in relation to the 2022 Share Award Scheme. In addition, approximately RMB1,417,000 (corresponding period of 2025: approximately RMB456,000) was capitalised in development costs.

(C) RESTRICTED SHARE SCHEME

On 5 January 2023, Lifetech Shenzhen adopted a Restricted Share Scheme ("2023 Restricted Share Scheme"). The purpose of the 2023 Restricted Share Scheme is (i) to recognise and motivate the contributions by certain eligible participants and to incentivise them and retain them for the continual operation and development of the Group; (ii) to attract suitable personnel for further development of the Group; and (iii) to provide certain eligible participants with a direct economic interest in attaining a long-term relationship between the Group and certain eligible participants.

22. SHARE-BASED PAYMENT TRANSACTIONS - *CONTINUED*

(C) RESTRICTED SHARE SCHEME - *CONTINUED*

In 2023, a total of 4,417,500 shares of Biotyx Medical held on behalf of Lifetech Shenzhen have been granted by Lifetech Shenzhen to certain employees at a price of RMB1.00 and the vesting period under the 2023 Restricted Share Scheme ranges from five to six years.

The following table discloses movements of the 2023 Restricted Share Scheme during the six months ended 30 June 2026 and 2025:

	Outstanding as at 30 June 2026	Outstanding as at 30 June 2025
Shares granted on 5 January 2023:	**4,417,500**	4,417,500

The fair value of shares granted was based on the recent transaction price of the shares.

For the six months ended 30 June 2026, the Group recognised approximately RMB3,780,000 (corresponding period of 2025: approximately RMB3,697,000) share-based payment expenses in profit or loss in relation to the 2023 Restricted Share Scheme. In addition, approximately RMB236,000 (corresponding period of 2025: approximately RMB318,000) was capitalised in development costs.

(D) EQUITY-SETTLED SHARE-BASED PAYMENT EXPENSES RECOGNISED IN THE CONSOLIDATED STATEMENT OF PROFIT OR LOSS

	Six months ended 30 June	
	2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Cost of sales	**2,194**	1,577
Research and development expenses	**13,099**	8,922
Administration expenses	**58,169**	54,635
Selling and distribution expenses	**49,596**	128,366
	123,058	193,500

23. OPERATING LEASES

THE GROUP AS LESSOR

All of the investment properties held by the Group for rental purpose have committed leases for the next 1 to 10 years.

Undiscounted lease payments receivable on leases are as follows:

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Within one year	27,448	29,450
In the second year	19,737	21,471
In the third year	15,125	15,144
In the fourth year	12,153	12,127
In the fifth year	6,275	8,898
Over five years	3,498	4,896
	84,236	91,986

24. CAPITAL COMMITMENTS

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Capital expenditure in respect of acquisition of property, plant and equipment - contracted for but not provided in the condensed consolidated financial statements	3,357	15,787

25. RELATED PARTY DISCLOSURES

(A) SIGNIFICANT RELATED PARTY TRANSACTION

The Group entered into the following transactions with the related party during the six months ended 30 June 2026 and 2025.

		Six months ended 30 June	
Relationships	**Nature of transactions**	**2026 RMB'000 (Unaudited)**	2025 RMB'000 (Unaudited)
Associate	Purchase of consulting services	**7,143**	8,260
	Providing equipment leasing	**563**	563
		7,706	8,823

(B) COMPENSATION OF KEY MANAGEMENT PERSONNEL

The remuneration of key management personnel during the period, excluding share-based payment expenses, was as follows:

	Six months ended 30 June	
Nature of transactions	**2026 RMB'000 (Unaudited)**	2025 RMB'000 (Unaudited)
Short-term employee benefits	**16,807**	14,937
Post-employment benefits	**337**	189
	17,144	15,126

The remuneration of key management personnel is determined by reference to the performance of individuals and market trends.